[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Next Article in Journal
Effects of Mineralocorticoid Receptor Blockade and Statins on Kidney Injury Marker 1 (KIM-1) in Female Rats Receiving L-NAME and Angiotensin II
Next Article in Special Issue
The Molecular Regulatory Mechanism in Multipotency and Differentiation of Wharton’s Jelly Stem Cells
Previous Article in Journal
Pathophysiological Effects of Various Interleukins on Primary Cell Types in Common Heart Disease
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 7
10.3390/ijms24076499
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Impact of Environmental and Epigenetic Changes on Mesenchymal Stem Cells during Aging

by
Nicholas Smith
1,2,†,
Suzanna Shirazi
1,2,†,
Dimitrios Cakouros
1,2,* and
Stan Gronthos
1,2,*
1
Mesenchymal Stem Cell Laboratory, School of Biomedicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5001, Australia
2
Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2023, 24(7), 6499; https://doi.org/10.3390/ijms24076499
Submission received: 31 January 2023 / Revised: 22 March 2023 / Accepted: 28 March 2023 / Published: 30 March 2023
(This article belongs to the Special Issue Genomics and Epigenetics of Stem Cell)
Browse Figures
Figure 1
<p>Molecular regulation of MSC cell fate. MSC differentiation is driven by a number of master regulators into the various lineages, including osteoblasts (Runx2), adipocytes (PPARy2) and chondroblasts (Sox9). Aged MSC show changes in phenotypes and differentiation properties, an effect of the changing epigenetic landscape within the cell.</p> "> Figure 2
<p>Regulators of DNA methylation. CpG methylation and the factors involved in writing (DNMT), reading (MBD containing proteins) and executing the silencing of genes (repressors). This mark is able to be removed or inhibited by the activity of DNA hydroxymethylases (TETs) and miRNA targeting DNMT. Receptor Activator of Nuclear Factor-kappa B (RANK).</p> ">
Review Reports Versions Notes

Abstract

:
Many crucial epigenetic changes occur during early skeletal development and throughout life due to aging, disease and are heavily influenced by an individual’s lifestyle. Epigenetics is the study of heritable changes in gene expression as the result of changes in the environment without any mutation in the underlying DNA sequence. The epigenetic profiles of cells are dynamic and mediated by different mechanisms, including histone modifications, non-coding RNA-associated gene silencing and DNA methylation. Given the underlining role of dysfunctional mesenchymal tissues in common age-related skeletal diseases such as osteoporosis and osteoarthritis, investigations into skeletal stem cells or mesenchymal stem cells (MSC) and their functional deregulation during aging has been of great interest and how this is mediated by an evolving epigenetic landscape. The present review describes the recent findings in epigenetic changes of MSCs that effect growth and cell fate determination in the context of aging, diet, exercise and bone-related diseases.

1. Characterisation of MSC

German pathologist Julius Cohnheim was the first to describe fibroblastoid-like cells originating from the bone marrow of rabbits and chickens with the ability to form mineralised ossicles when transplanted into muscle [1]. Almost a century later, Friedenstein and colleagues reported on the isolation and ex vivo expansion of clonal adherent stromal precursor cells from the bone marrow of rodents capable of giving rise to osteoblasts, adipocytes and chondrocytes [2]. The colony-initiating cells were denoted as colony-forming units-fibroblast (CFU-F), which were later identified in human bone marrow aspirates [2,3]. Clonal analyses of ex vivo expanded human CFU-F were also found to undergo self-renewal, support a hematopoietic stem cell niche and facilitate wound repair, as well as exhibit immunomodulatory properties [4,5,6,7,8]. These stromal precursors have subsequently been referred to as skeletal stem cells, mesenchymal stem/stromal cells (MSC), stromal precursor cells and bone marrow-derived mesenchymal stromal cells (BMSC). Although there has been major progress in identifying MSC-associated markers, no single cell surface marker has been identified as MSC-specific to date. STRO-1, CD44, CD49a, CD73, CD90, CD105, CD106, CD146, CD166 and CD271 are known to discriminate MSC from many other cell types [5,9,10,11]. Furthermore, the expression of these markers can be compromised by culture conditions and passage number [12]. Other selection markers include Leptin-receptor+, PDGF-receptor+, CXCL12+, α-smooth muscle actin+, Prx1+, Nestin+, Mx1+, multi-potential perivascular cells or reticular cells, with varying capacities to support haematopoiesis [5,13,14,15,16,17,18,19]. Alternate MSC isolation protocols are based on negative selection approaches by eliminating non-MSC accessory cells via the expression of antigens such as CD11b, CD14, CD19, CD31, CD34, CD45, CD45, CD79a, Glycophorin-A and HLA-DR [5,20]. More recently, CD200 [21] and Gremlin [22] have been shown to identify precursor populations in osteoblasts and chondrocytes but not adipocytes. Further investigations identified CFU-F or MSC-like populations residing in other adult tissues such as adipose, dental pulp, periodontal ligament and peripheral blood [23,24,25,26] acting as stem cell reservoirs for tissue homeostasis and repair after an injury, disease or aging. However, MSC-like populations derived from different tissues are known to have differential growth and developmental properties based on the epigenetic memory of each cell population dependent on the tissue of origin [27,28].

2. Biological Changes Associated with Aging MSC and the Skeleton

The skeleton is the major tissue in supporting human structure and movement. It is also considered an endocrine organ in maintaining calcium and glucose homeostasis [29]. Bone health is a major challenge in an aging populations commonly found in developed countries, where it is often linked to a more sedentary lifestyle. This has led to lower bone density in the elderly, associated with an increase in the incidence of major fractures and severe long-term disability [30,31], with mortality rates of 15–25% [32]. Therefore, aging presents as a major risk factor for skeletal disease in developed countries [33].
DNA damage, cellular stress responses and alterations in both the genome and epigenome can cause a decline in healthy tissue homeostasis and lead to a host of changes at both the cellular and tissue level. The epigenetic landscape within stem cells is a dynamic process [27,34], where the ability to undergo self-renewal and differentiation into functional, organ-specific cell types becomes increasingly limited during aging. Consequently, the functional capacity of MSC to maintain tissue homeostasis is compromised due to phenotypic alterations linked with the cellular aging and senescence of MSC, which ultimately affect their regenerative properties [35].
In postnatal organisms, BMSC retain their ability to regenerate tissues following bone fractures, articular cartilage injuries and other traumatic injuries of connective tissue. Osteoarthritis, osteoporosis and systemic inflammatory conditions such as rheumatoid arthritis are among the most common and disabling musculoskeletal degenerative disorders often associated with aging [36]. Other risk factors include obesity, alcohol intake, smoking, family history of hip fractures and joint trauma [37]. As with other stem cell populations, there are some alterations in the composition, function and structure of MSC due to both cellular intrinsic and extrinsic aging-related mechanisms [28,38]. Some intrinsic aging mechanisms that are common between all cell types include impaired DNA repair, telomere shortening, alteration in gene expression and epigenetic drift [10,28,39,40]. In regard to extrinsic mechanisms of cellular aging, changes in the tissue composition and microenvironment via hormonal and growth factor signalling, as well as an increase in inflammatory cytokines, seem to play a crucial role in MSC senescence [41,42,43]. Studies have also shown that, as MSC age, there is not only a decrease in the osteogenic and chondrogenic differentiation potential but also a shift towards adipogenic development at the expense of osteo/chondrogenic differentiation [27,41,44,45,46,47]. Therefore, bone remodelling is compromised with a shift towards bone resorption, which causes trabecular and cortical thinning with a rise in cortical porosity [48]. Furthermore, aged MSC express less pro-inflammatory factors and show weakened immunomodulatory potential, which has been associated with the early senescence of MSC [49,50]. Endogenous signals, even in the absence of any damaging stimuli, drive “age-associated low-grade inflammation known as ‘inflammaging’” [51,52], where a recent study has confirmed the role of inflammaging in declining MSC numbers and functions affecting bone healing [53]. The design of therapeutic agents to slow down MSC aging and alleviate disease is dependent on our understanding of the molecular changes that drive MSC aging. One of the pillars of aging for all organisms is epigenetic drift, where changes in the epigenome drive the deregulation in cell growth and differentiation. Discovering the key players and their modes of action have been the focus of recent studies.

3. Epigenetic Regulation of MSC Growth and Function

Epigenetics refers to heritable alterations in gene expression that cannot be attributed to alterations in the DNA sequence and range from DNA methylation and histone modifications to alterations in the non-coding RNA expression and chromatin structure [54]. These epigenetic alterations regulate gene expression by altering the accessibility of the DNA to transcription and accessory factors, as well as altering the expression at the translational level by interfering with mRNA (Figure 1). The result of this is a network of modifications that can shift throughout the lifespan of an organism, with a changing landscape as we interact with our environment through lifestyle choices such as diet and exercise (Table 1). These changes ultimately remodel the chromatin structure and impact stem cell biology. Interactions between lifestyle factors and epigenetic patterns in an increasingly aging population has highlighted the complex nature of “aging”, with a host of epigenetic factors being investigated into how they regulate MSC growth and function (Figure 1).

3.1. Structural Changes of Chromatin in Aged MSC

The relationship between the chromatin structure, nucleosome positioning and BSC aging is a recent phenomenon that is gaining traction, as its importance in transcription, DNA damage and genomic stability is essential. Recent studies have examined genome-wide chromatin accessibility in adipose-derived MSC (AMSC) using the assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq), which found that chromatin is generally more open in AMSC compared to somatic cells [55], especially around promoters and five prime untranslated regions (5′UTR), allowing for greater plasticity in stem cells. Surprisingly, the nucleosome positions remain relatively stable during aging, as assessed by NucleoATAC-seq, indicating how robust stem cells are. Subtle changes, however, are observed around gene loci regulating stress responses. This was evident for genes encoding SUMO proteins, as sumoylation is an important post-translational modification that occurs to stress-related proteins. The nucleosome re-positioning in this region allows for a greater expression of SUMO-1 under stress, giving rise to a unique stem cell-specific protective mechanism [55]. The machinery that is central to chromatin remodelling includes the ATPase-dependent chromatin remodelling SWI/SNF family, which consists of Brahma-related gene 1 (Brg-1) and Brahma (BRM). These proteins can slide nucleosomes to either promote open or closed chromatin [56,57]. Any changes in Brg-1 expression in BMSC results in senescence, partly due to the silencing of Nanog expression due to the recruitment of DNA methyltransferase 1 (DNMT1) and histone deacetylase 1 (HDAC1), which methylates DNA and deacetylates histones, respectively, altering the nucleosome architecture [58]. In agreement with its role in cellular senescence, senescent BMSC have been shown to lose Nanog expression [59].
Another chromatin structural protein is CBX4, which is part of the polycomb repressive complex 1 (PRC1) and was found to be downregulated in aged human BMSC and in BMSC from Werner syndrome patients who exhibit premature aging [60]. Surprisingly, there was no change in genomic instability or differentiation in CBX4 knockout BMSC, and differentiation proceeded normally; however, BMSC underwent senescence, where the RNAseq analysis identified 306 upregulated genes and 332 downregulated genes. Identification of the binding partners by mass spectrometry identified 262 proteins, most of them nucleolar proteins. CBX4 was found to bind to rDNA repeats, and its loss led to reduced heterochromatin formation in the nucleolus, together with downregulation of histone 3 lysine 9 tri-methylation (H3K9me3) and increased ribosome expression.
Gene expression profiling of old BMSC identified another chromatin structural protein, nucleosome assembly protein 1-like 2 (NAP1L2), where increased expression correlated with senescence and impaired osteogenesis [61]. NAP1L2 was found to augment chromatin accessibility by affecting histone 3 lysine 14 acetylation (H3K14Ac) by recruiting the HDAC Sirt1 to the osteogenic gene promoters and was upregulated in patients with osteoporosis. Additional studies examining chromatin structures in old BMSC using ATAC-seq identified a decrease in chromatin accessibility, with 6500 sites becoming more accessible and 8250 being less accessible [62], with the gene ontology (GO) analysis showing enrichment for cell differentiation genes. Chromatin accessibility was largely influenced by a global decrease in H3 and H4 acetylation, as well as H3K27Ac in gene enhancers. Genes that gained H3K27Ac corresponded to the metabolism. A novel mechanism was discovered where the export of acetyl-CoA from the mitochondria in the form of citrate was impaired and therefore led to reduced histone acetylation. This was evident in older and osteoporotic patients. The observed effect on aged BMSC was reversed simply by the addition of acetate, illustrating the importance of histone acetylation and chromatin structures.
More recent studies identified zinc finger protein with KRAB and SCAN domain 3 (ZKSCAN3) to be downregulated in aged BMSC, resulting in senescence. ZSCAN3 was found to maintain heterochromatin via its interaction with lamina proteins. Its downregulation results in the detachment of lamin-associated domains with the nuclear lamina, more accessible chromatin and the expression of repetitive sequences [63].
A recent multi-omics approach on aged BMSC, including ATAC-seq, proteomics and RNAseq, identified 2152 deregulated genes [64] with BMSC aging hotspots affecting distinct chromatin subsets. Downregulated proteins consist of the cell cycle, chromatin regulation, chromatin remodelling and RNA-processing proteins, whilst upregulated genes were involved in autophagy. Age-sensitive chromatin regions were enriched in bivalent domains, heterochromatin and repressor polycomb domains, which dictate the lineage determination of BMSC. The expression of adipogenic transcription factors increased, whilst the osteogenic factors decreased. Most importantly, aged-sensitive chromatin regions were enriched for single-nucleotide polymorphisms (SNPs) associated with bone density, body mass index and immune diseases [64], illustrating their relevance and how multiomic approaches can uncover genomic regions and proteins that drive age-associated diseases.
Although only the latest findings have been covered in this review, they reinforce previous studies that the chromatin structure is essential for BMSC self-renewal and longevity by enforcing the formation of heterochromatin, genomic stability and proper expression of differentiation genes. Chromatin remodelling and structural proteins are carefully balanced to ensure the structural integrity, and their deregulation is another layer contributing to the epigenetic drift, driving BMSC aging. Chromatin readjustments as part of epigenetic modifications that occur with aging cause changes in the gene expression profile and lineage determination, where changes in the histone methylation, acetylation, DNA methylation and hydroxymethylation are among some common epigenetic modifications between different cell types in the process of MSC aging [65].

3.2. Role of DNA Modifications in MSC Growth and Function

DNA modifications—in particular, DNA methylation—is a major player in the epigenetic landscape and is one of the most prolific modes of epigenetic regulation in MSC differentiation [66,67] (Figure 2). The methylation of 5-methylcytosine (5-mC) acts as the primary form of DNA modification, leading to gene silencing [66]. Cytosine-rich regions of DNA are known as CpG islands and are frequently found around promoter regions, where the methylation status of the cytosine residues determines the transcriptional activity of the gene [68]. Upon comparison between MSC derived from the various mesenchymal tissues, differences in the methylation status were found between the various cohorts based on the tissue of origin [69]. It was reported that MSC derived from adipose tissue were hypomethylated at the PPARy promoter whilst being hypermethylated at the Runx2 locus. Conversely, BMSC were hypomethylated at the Runx2 promoter, whilst PPARy remained hypermethylated. In addition, the methylation status at the Sox9 locus was comparable between the two cohorts, with the methylation status only being slightly lower in the bone marrow-derived cohort.
The methylation of CpG islands in MSC plays a critical role in lineage determination, and together with the Ten-Eleven Translocase (Tet) family of DNA hydroxymethylases, controls self-renewal [65]. The three members of the Tet family (Tet1, Tet2 and Tet3) remove the 5mC mark on the DNA via the hydroxylation of 5mC to 5hmC [65] and further modifications leading to base excision repair and removal of the methyl mark. Tet1 and Tet2 have both been found to play roles in both maintaining the pluripotency in embryonic stem cells (ESC) [70] and driving the differentiation of BMSC into osteogenic and adipogenic lineages [65,71]. Tet1 has been shown to associate with NANOG to enhance the expression of pluripotency genes, Esrrb and Oct4, to maintain naïve pluripotency in ESC [72] whilst associating with Sin3a to repress the transcription of differentiation genes [73]. Conversely, Tet2 has been shown to remove silencing marks on osteogenic and adipogenic genes [65], with the knockdown of Tet2 producing a downregulation of the osteogenic genes Runx2, Bmp2, Osteopontin and Osteocalcin. Studies on ovariectomised mice have shown decreased 5hmC levels accompanied by bone loss [71], with further studies being performed to confirm the roles of Tet1 and Tet2 in both aging and pathological bone loss.
The activity of DNA methyl transferases (DNMT) has been shown to play a role in BMSC aging, highlighting a constantly changing methylome throughout human development. Pluripotency factors such as OCT4, involved in BMSC self-renewal and growth, are impacted by DNMT activity [43]. This study showed OCT4 represses p21 expression via the upregulation of DNMT, leading to increased methylation of the p21 promoter and inhibition of cellular senescence in hair follicle mesenchymal stromal cells. Furthermore, the role of DNMTs in cellular senescence and aging has been supported, with further studies implicating decreased methylation in senescent cells [45] via the downregulation of DNMT1 and DNMT3b. Other investigations reported that DNMT inhibition in MSC led to an increase in activity of cyclin-dependant kinase inhibitors, most notably p16INK4A and p21CIP1, and, ultimately, a reduction in EZH2 and BMI1 expression, associated with replicative senescence in MSC [74].
Recent studies have reported that the expression of the DNA N6-methyladenosine (N6-mA) demethylase, Alkbh1, is reduced in aging stem cells populations [34,63], with the depletion of Alkbh1 resulting in enhanced bone loss and increased bone marrow adiposity. A significant reduction in Osteopontin expression, a known regulator of MSC fate determination in aging [75], was also observed in Alkbh1 null animals. Conversely, overexpression of Alkbh1 was reported to alleviate age-related bone loss by promoting osteogenesis. Moreover, an increase in N6-mA was observed around the promoter region of this gene, indicating Alkbh1 may regulate BMSC lineage determination through adenosine methylation of the Osteopontin promoter region. As well as acting as a DNA methyl mark, N6-mA also acts as an abundant mRNA modification and has been linked to cancer progression. Conversely to Alkbh1, methyl transferase-like 3 (METTL3) is a major factor in the adenosine methylation of RNA molecules and has been recently implicated in BMSC osteogenesis via post-transcriptional modification of the Runx2 transcript [76]. In an analysis of osteoporotic samples derived from ovariectomised mice, it was found that osteoblast differentiation markers Collagen-I, Alkaline Phosphatase (ALP) and Bone Morphogenic Protein 2 (BMP2) were all downregulated compared to the control groups, as well as significantly downregulated N6-mA levels in those cohorts, along with known adenosine methyl transferases METTL3 and METTL4. Upon the overexpression of METTL3 in BMSC, it was found that osteogenic differentiation markers were upregulated, and functional differentiation assays showed an increase in ALP activity and mineral formation. The immunoprecipitation analysis showed an enrichment of a variety of miRNAs, with miR-320 being the most strongly N6-mA methylated of the cohort. Further elucidation of miR-320 targets identified Runx2 as being a key target gene, with the overexpression of miR-320 causing a pronounced decrease in Runx2 expression. These findings proposed METTL3 as a pro-osteogenic or anti-osteoporotic factor, with overexpression of this methyltransferase leading to the downregulation of miR-320, a now established silencing element targeting known osteogenic biomarkers such as Runx2.
Sclerostin (SOST) is a glycoprotein secreted by osteocytes in response to mechanical stress on the bone and has been shown to play a role in bone formation and remodelling, with the loss of SOST resulting in Van Buchem disease, associated with endosteal hyperostosis of the mandible, skull, ribs and clavicles, as well as diaphysis of the long bones [77,78]. Studies have reported an association with altered SOST expression and changes in the bone mineral density in individuals, particularly with single-nucleotide polymorphisms (SNPs) at the SOST promotor, leading to lower bone density and osteoporosis [79,80]. The regulation of established pathways such as Wnt/b-catenin by SOST [81], as well as transcription factor regulation of SOST by Osterix and Runx2 [79], have been well documented; however, information on the epigenetic mechanisms of gene regulation remains incomplete. It has been reported that altered methylation of the SOST promoter regulated the osteoblast–osteocyte transition [82], as well as a correlation between an increase in methylation and increased fracture risk in post-menopausal women. More recently, SOST promoter methylation was found to disrupt the transactivation of key transcription factors Osterix, ERa and RUNX2 via the impairment of transcription factor binding [83]. The chromatin immunoprecipitation (ChIP) analysis revealed that Osterix, Era and RUNX2 bind directly to the SOST promoter, with a decreased binding ability found in osteoporotic patients due to elevated levels of CpG methylation.
When it comes to bone remodelling, the balance between osteoclast and osteoblast activity is critical to maintain healthy bone formation. Receptor Activator of Nuclear Factor-kappa B (RANK) and binding of its ligand (RANKL) are crucial in the development and maturation of osteoclast cells in the bone microenvironment. Conversely to this, osteoprotegrin produced by osteoblasts is able to sequester RANKL by acting as a decoy receptor in order to temper the bone resorption. The role of DNA methylation in this system has been elucidated in a study using osteoporotic patient samples [84]. The study showed an increase of the RANKL transcript in osteoporotic samples, coupled with a depletion of OPG, leading to a balance favouring bone resorption through osteoclast activity. It was found that 32 CpG sites of RANKL become highly demethylated in the osteoporotic group compared to the control. Accompanying this, it was found that OPG was largely hypomethylated in both groups, but the levels of DNA methylation in the osteoporotic group were significantly greater. These findings suggest that the imbalance of the RANKL-OPG system, caused by DNA methylation, leads to a favouring of osteoclast development and, thus, bone resorption and a bone loss phenotype.

3.3. MSC Aging and the Deregulation of Histone Modifications

Histone modification changes are part of the epigenetic drift that occurs in aging stem cells, which is the centrepiece of the information theory of aging [27]. This evidence came to fruition by examining whole genomes using the single-cell ChIP-seq analysis, which revealed cellular heterogeneity within the same tissue [85]. The epigenetic changes alter gene expression, regulating important signalling pathways essential for cell renewal, as well as altering the chromatin structure to compromise genetic stability, leading to transcriptional noise, where stem cells are functionally compromised and lose cell identity. Generally, histone modifications occur within the first 30 amino acids of the amino terminal domains of histones. The common residues are histones H3K4, H3K9, H3K27, H4K20 and H2AK119. The modifications include acetylation, methylation, phosphorylation, ubiquitination and sumoylation [86].
H3K27 trimethylation (H3K27me3) is a repressive mark and essential for embryonic development. As part of the bivalent domain with H3K4me3, it is crucial for the stem cell renewal and proper differentiation [87]. We and others have shown that the H3K27me3 levels increase in aged or ovariectomised murine BMSC [88,89,90,91]. The histone methyltransferase Ezh2 is responsible for H3K27me3 (45) and has been found to increase H3K27me3 on Wnt12, Wnt6, Wnt10a, Runx2 and Bglap in ovariectomised mice, which mimics aging by altering the differentiation to favour adipogenesis at the expense of osteogenesis [89]. The enforced expression of Ezh2 inhibited BMSC osteogenesis in an in vivo ectopic bone formation model [91], whereas the deletion of one allele of Ezh2 in BMSC leads to increased bone volume and bone length [92]. In contrast, the deletion of both alleles leads to reduced bone volume and length, premature senescence, depletion of the MSC pool and osteoporosis in adult mice [93]. Ezh2 was found to bind and regulate the expression of novel genes ZBTB16, MX1 and FHL1 involved in osteogenesis and adipogenesis [94], as well as the cell cycle inhibitor genes, including P15INK4b, P16INK4a, P21CIP1 and P27 KIP1 [93].
Conditional deletion of Ezh2 using the Nestin promoter as the driver results in the premature senescence of MSC, where aged MSC express reduced Ezh2 levels compared to their younger counterparts [93]. It was further found that the downregulation of Ezh2 results in less H3K27me3 on the promoters of p15INK4b, p16Ink4a, p27 and p21, promoting senescence and decreasing self-renewal [93]. In addition, immature BMSC express higher levels of the HLH transcription factor Twist-1, which recruits Ezh2 to the p16Ink4a locus, repressing transcription and senescence [90]. During replicative senescence, the levels of Twist-1 decrease and Ezh2 levels on the p16Ink4A locus decrease, leading to increased p16 expression and senescence [90]. In another novel study, Ezh2 was shown to increase the H3K27me3 of Foxo1, inhibiting the antioxidant defence system [95]. By blocking Ezh2 activity, the antioxidant system was reactivated, promoting osteogenesis in aged human BMSC. The Ezh2-mediated suppression of osteogenesis was reversed when using antioxidants to eliminate reactive oxygen species (ROS) in aged BMSC.
The examination of epigenetic changes in aged human BMSC has shown that regions of the genome that acquire DNA hypermethylation are associated with repressive histone marks H3K27me3, H3K9me3 and Ezh2 enrichment [96]. DNA hypomethylated sites are associated with the active enhancer mark H3K4me1. These results show that the well-known changes in age-related DNA methylation in BMSC are regulated by specific histone marks. The H3k27me3 mark is removed by the histone demethylases KDM6A/KDM6B. the knockdown of KDM6A in human BMSC promotes adipogenesis and reduces osteogenesis and has been shown to bind to the transcription start site (TSS) of Runx2 and Bglap [91]. The conditional deletion of KDM6A in early mesenchyme has shown subtle defects in bone formation in the cranium and long bones (unpublished data), suggesting redundancy with other KDM6 family members. KDM6B has been found to be reduced in BMSC from aged mice, and the knockout of KDM6B leads to severe bone defects [97]. These studies emphasised the importance of correct spatial and temporal regulations of genomic H3K27me3 in the self-renewal and differentiation of stem cells and the impact they have on mesenchymal stem cell aging (Table 2).
H3K9 methylation is also a repressive mark associated with heterochromatin, and increasing levels are associated with MSC aging [75]. An important study found that the demethylase KDM4B, which demethylates H3K9me3, H3K9me2, H3K36me3, H3K36me2, H4K20me2 and H1K26me3, is essential for BMSC self-renewal [75]. The loss of KDM4B leads to BMSC exhaustion, loss in self-renewal and promotion of adipogenesis at the expense of osteogenesis [75]. The genome-wide ChIP analysis found that KDM4B was present on Wnt promoters and Runx2, with its deletion leading to elevation of the H3K9me3 levels [75] and suppression of gene expression and osteogenesis. An additional study discovered that the H3K27me3 and H3K9me3 global levels increased in murine aged BMSC (18 month) compared to young BMSC (2 month), and the same was evident in BMSC derived from osteoporotic samples [88]. This coincided with a reduction in the H3K9me3 demethylase KDM4B and the H3K27me3 demethylase KDM6B. In another study, KDM4A was found to activate the expression of DLX2 and DLX3 in response to Bmp4/7, and the GO analysis confirmed KDM4B controls the genes involved in skeletal development and osteoblast differentiation. KDM6B controlled the expression of Hox genes, and the GO analysis confirmed its regulation of skeletal development and matrix organisation. A similar study found that the loss of KDM4B accelerated aging and high-fat diet-mediated bone loss due to increased senescence and BMSC exhaustion [75]. Profiling histone demethylases during the replicative senescence of BMSC identified the H3K9me3 demethylases KDM3A and KDM4C to be upregulated, whereas the H3K9me3 methyltransferase SUV39H1 was downregulated, affecting the expression of chromosome condensation genes such as condensing [98], which altered the nuclear architecture.
The transcriptional activator H3K4me3 has been shown to be downregulated in osteoporotic murine BMSC [99]. It is regulated by the methyltransferase ASH1L, a member of the Trx family, which was reported to be downregulated in ovariectomised mice [99]. In contrast, the H3K4me3 demethylase KDM5A was upregulated, leading to lower H3K4me3 levels. KDM5A was found to target Hoxa10, Runx2, Osterix and Sox9 promoters, which displayed low levels of H3K4me3 [99]. The knockdown of ASH1L results in a decrease in H3K4me3 along the promoters of Hoxa10, Runx2, Osterix and Sox9 [100].
H3K36me3 is important for transcriptional elongation and restoring the proper chromatin structure following gene transcription. The SET domain-containing 2 protein (SETD2) is responsible for H3K36me3, and its conditional deletion promotes adipogenesis and impairs osteogenesis, resulting in bone loss [101], resembling osteoporosis. Then, 983 genes show a loss of gene expression and H3K36me3 enrichment [102]. Then, 904 genes were upregulated and 913 genes downregulated [102]. H3K36me3 was found to be present on gene bodies, promoters and 3′UTR but absent from TSS.
Epigenetic rejuvenation of BMSC is becoming a new strategy to alleviate the aging phenotype. Inhibitors to HMTs and HDMs are used in the clinic in the cancer field, displaying safety and efficacy. It has been demonstrated that inhibiting Ezh2 activity using DZnep and SUV39H1 activity with chaetocin can alleviate osteoporosis. DZnep treatment can increase trabecular bone in ovariectomised mice [89], and chaetocin increases bone tissue in vivo by decreasing H3K9me3 on Wnt promoters [103], demonstrating that epigenetic-targeted therapies may be an effective means of rejuvenating aged stem cells.

3.4. Histone Acetylation Changes during Aging of Mesenchymal Stem Cells

The aging of BMSC is also associated with changes in histone acetylation (Table 2)—in particular, H3K9, K14 and K56 acetylation. The long-term culture of placental MSC results in the upregulation of HDAC4, 5 and 6, resulting in a decrease in the acetylation of H3 and H4. Acetylation of the pluripotency gene promoters Tert, Oct4 and Sox2 decreases together with the gene expression, resulting in a decrease in stem cell self-renewal [104]. Studies in adipose-derived MSC show that, during replicative senescence, the levels of HDAC1 and 2 decrease together with the polycomb group proteins (PcG). This promotes H3 acetylation of the KDM6B promoter, which was verified by the knockdown of HDAC1 and 2. The increase in KDM6B results in a decrease in H3K27me3 along the p16Ink4A locus increasing expression and senescence [105]. During BMSC senescence, it was found that the expression of HDAC1 and 2 decreases rapidly. HDAC1 and HDAC2 upregulate the expression of Ezh2, BMI1 and SUZ12 and downregulate KDM6B [105]. The downregulation of HDAC1 and HDAC2 decreases the expression of Ezh2, BMI1 and SUZ12 and increases KDM6B, reducing the H3K27me3 levels on the p16Ink4A promoter, promoting senescence.
H3K9 acetylation has been shown to be drastically downregulated in aged BMSC [106] and is deposited by general control nonderepressible 5 (GCN5), p300/CBP-associated factor (PCAF) and removed by HDAC9. H3K9 acetylation is a primary target for GCN5, which has been shown to reduce dramatically in aged BMSC, and in osteoporotic BMSC from ovariectomised mice [107]. Furthermore, the siRNA-mediated knockdown of GCN5 compromises H3K9 acetylation, especially on the promoters of Wnt genes, compromising osteogenesis [107]. Although PCAF has been shown to acetylate H3K9 on BMP2, BMP4 and Runx2 promoters [108], its role in aging is yet to be determined. A similar study showed the expression of HDCAC9 to increase during age-related bone loss coinciding with a decrease in H3K9 acetylation. This resulted in impaired osteogenesis, which was associated with abrogated autophagy in BMSC. The gene expression levels of key autophagy genes were downregulated in aged BMSC, with the increased binding of HDAC9 to autophagy genes ATG7, BECN1, Lc3a and Lc3b in aged BMSC [106]. This shows the importance of autophagy and the regulation of autophagy by histone acetylation in driving osteogenesis. Pluripotency genes also show dramatic changes in acetylation during BMSC aging, with a decrease in H3K9 and K14 acetylation seen on promoters for Oct4, Sox2 and Tert, resulting in decreased expression [109] and compromising their self-renewal.
Another important acetylation mark is H3K56 acetylation, which increases in aged BMSC. One of the key enzymes essential for depositing this mark is the NAD+-dependent Sirt6 enzyme [110]. The deletion of Sirt6 in BMSC results in the reduced expression of the antioxidant HO-1, as SIRT6 is responsible for H3K56 deacetylation on this promoter; an increase in ROS, oxidative stress and impaired osteogenesis and chondrogenesis. Senescence is accelerated due to the increased expression of p16 and p21 [111].
Since senescence is a hallmark of aging, and the ablation of senescent cells in a whole animal prolongs the overall lifespan [74,112]. A recent study performed a genome-wide CRISP-Cas9 loss of function screen using precursor mesenchymal cells from a premature aging mouse model known as Werner syndrome [113]. Approximately 19,000 coding genes were targeted, where long-lived cells following serial passage indicated an abrogation of senescence. The cells that escaped senescence displayed youthful features, including increased proliferation, reduced senescence and restored nuclear architecture. Knockdown of the histone acetyl transferase KAT7 reduced senescence and restored the ability of the passaged cells to undergo osteogenic differentiation. Heterochromatin formation was also restored, resembling young BMSC. One-third of the deregulated genes were restored following KAT7 knockdown, including the genes involved in chromosome organisation and DNA packaging. In contrast, the overexpression of KAT7 induced heterochromatin loss, increased p16 and p21 expression and was found to acetylate H3K14 of the p15Ink4b promoter. Moreover, KAT7 and p15Ink4b were found to be increased in aged human BMSC (79–81 years old) versus young BMSC (16–28 years old). Interestingly, lentiviral-mediated deletion of KAT7 in aged mice targeting the liver increased the overall health and lifespan of these animals. Similar screens have identified the acetyltransferase p300 [114] to prolong the lifespan, whereas the knockout of SIRT6 leads to an increase in H3K9Ac and H3K56Ac in association with increased rates of aging [111,115].
Following transcription, the closed chromatin state is restored by various complexes, including the histone demethylase Kdm5b [116,117] and the DNA methyltransferase Dnmt3b [116]. These proteins are recruited by H3K36me3, and any deregulation in this process leads to cryptic transcription, where transcripts are made from internal TSS. An interesting study used culture-expanded MSC as an in vitro model of aging to examine exon-based transcription, where downstream exons displaying higher transcripts per kilobase million than the first exon indicates cryptic transcription. Highly expressed genes were found to have cryptic transcription in aged MSC and HSC [118]. DAVID clustering revealed clusters related to telomere maintenance, protein folding and translation and endoplasmic reticulum function, indicating that cryptic transcripts will interfere with these functions. Using the ChromHMM analysis, the chromatin structure was examined to discover the greatest change was a loss of constitutive heterochromatin; gain of facultative heterochromatin and decrease in overlap between H3K4me1, H3K27Ac and H3K36me3, while H3K4me1 and H3K27Ac distribution is wider. H3K36me3 in gene bodies becomes depleted. Interestingly, H3K36me3 restores the chromatin structure once RNA polymerase II moves through. Its depletion will lead to a more open conformation, promoting cryptic transcription. Further analysis discovered that the TSS around cryptic start sites also contained H3K4me1, K27Ac and K4me3 and less CpG DNA methylation, allowing a more permissive chromatin state. Given that the cryptic transcripts are involved in telomere maintenance and proteostasis, it is predicted that these systems are compromised during BMSC aging.

3.5. Non-Coding RNAs (miRNA, lncRNA) Regulation of MSC

Non-coding RNAs, such as miRNAs and long non-coding RNA (lncRNA), are functional RNA molecules that are not translated into proteins but are able to regulate the expression of genes post-transcription [119]. These non-coding RNAs are transcribed, before modification by enzymes DROSHA and DGCR8 in the nucleus, then further modified in the cytoplasm by DICER, allowing for mature miRNA to silence and degrade functional RNAs and silence the protein expression of target genes [119].
Various miRNAs are able to exhibit control over MSC differentiation during a number of stages in the process through regulation of the master regulators (Runx2, Sox9 and PPARγ) [120,121,122] via osteogenic markers such as ALP [123] and Osx [124] in developing osteoblasts. Targeting of the master regulators has been well documented, with three master regulators listed above all able to be targeted by miRNA. Families of miRNA are known to potently target Runx2 [125], such as miR-23a and miR-30c, to control early osteogenesis, while miR105 has been shown to inhibit Sox9 to enhance osteogenic differentiation over chondrogenesis [121]. Therefore, it appears that epigenetic control over these transcription factors in both the early and late stages of bone cell differentiation is an essential process in regulating osteogenesis, which additionally requires coordinated regulation by miRNA targeting different signalling components mediating BMSC cell fate determination.
Investigations into miRNA since their discovery [126] have been categorised through the depletion of DGCR8 in ESC before rescue via miRNA mimics [127] to elucidate the roles of a host of miRNAs in the cell cycle and pluripotency, amongst others. Using this technique, studies have shown how miRNAs miR-29a-3p and miR-30c-5p can affect MSC senescence and cellular proliferation through known epigenetic regulators SOD2 and DNMT3A [128]. DGCR8 and, as such, global miRNA depletion in human MSC caused a significant reduction in cell proliferation, along with enhanced senescence and increased ROS production through mitochondrial dysfunction compared to untreated cells. Comparisons of DGCR8-depleted cells and cells that have undergone replicative senescence showed the same canonical senescence pathways shared between the two cohorts, supported by a bioinformatics analysis, supporting the induction of senescence via miRNA depletion. SOD2 was found to be dysregulated upon DGCR8 knockdown, playing a role in enhanced ROS production and premature senescence. Elucidation of the mechanism discovered hypermethylation at the SOD2 promoter after DGCR8 loss, and upon further investigation, it was found that DNMT3A was upregulated in these cells, suggesting that DNMT3A is the intermediate regulator of SOD2 expression. Using predicted conserved miRNA families, it was found that miR-29 and miR-30 share high sequence homology, and upon exogenous expression in DGCR8 KO cells, were able to reduce the ROS, as well as decrease the senescence factors and increase the cell proliferation rate. Through the regulatory control of BMSC proliferation and ROS production, miR-29a-3p and miR-30c-5p can elicit control over the early stages in differentiation.
A number of miRNAs have been directly implicated in regulating osteogenesis, targeting many different genes and signalling pathways. Investigations have shown the relationship between different miRNAs and the activity of TWIST-1, a key transcriptional regulator of BMSC self-renewal and growth, as a suppressor of osteo/chondrogenic differentiation [123,129]. TWIST-1 has been shown to positively regulate miRNAs miR-199a and miR-124, inhibiting osteoblast function via Wnt signalling (miR-199) and the FGFR1, JNK and p38 pathways (miR-124) [130,131]. In addition, TWIST-1 was also found to upregulate miR-376c-3p in BMSC and cranial bone cells during growth and osteogenic differentiation [123]. It was reported that the inhibition of miR-376c-3p induced an increase in BMSC and cranial cell osteogenic potential, whilst the overexpression of miR-376c-3p suppressed cell proliferation and differentiation via the regulation of IGFR1/Akt signalling to inhibit the expression of key osteogenic genes such as Runx2, ALP, OPN and OCN. This presents miR-376c-3p as a regulator of mature osteoblast function and differentiation from the undifferentiated MSC form all the way until the mature osteoblast stage.
Other miRNAs have also been shown to play direct roles in bone development and during osteoporosis. Studies have described miRNA-19a-3p as playing a role in osteogenesis during normal and pathological conditions [132]. Prior to this, the clusters of miRNAs (miR-17-92), which include miRNA-19a-3p, have been reported to play a role in a number of malignancies, such as breast [133], lung [134] and gastric [135] cancers. Through transcriptome analysis, miR-19a-3p was shown to be downregulated in osteoporotic patient samples, whereas miR-19a-3p was upregulated in human MSC cultured under osteogenic inductive conditions. The predicted binding sites uncovered HDAC4 as a putative miR-19a-3p, part of the histone deacetylase family tasked with removing acetyl marks from histones and restricting gene expression via chromatin remodelling, adding a layer of control at the mature osteoblast stage [136]. The overexpression of miR-19a-3p was found to negatively regulate the protein level of HDAC4, leading to the increased expression of osteogenic markers such as ALP and overall osteogenesis through chromatin remodelling. A further study implicated the role of miR-181a/b-1 in osteogenesis and bone development, albeit through a different mechanism of action [137]. The data demonstrated an upregulation of miR-181a/b-1 in hypertrophic chondrocytes in long bones, suggesting a role in endochondral bone formation and chondroblast differentiation. An analysis of the cells taken from miR-181a/b-1 null mice identified the phosphatase and tensin homolog (PTEN) as a potential target gene, a known inhibitor of the PI3/AKT signalling pathway. PTEN knockout mice display an enhanced bone formation phenotype, where PI3K/Akt signalling is central in osteoblast differentiation and, thus, bone development [138,139]. Another key player in osteoblast differentiation and osteogenesis is Osx, a transcription factor essential for bone development [140]. Similar to the other factors, Osx can be modulated via epigenetic mechanisms, with miR-138 being a key established miRNA involved in the regulation of its activity via the Runx2 pathway [141] at the MSC to pre-osteoblast stage. The effect of miRNA regulation on a wide array of different factors spanning the lifespan of osteoblasts from MSC to functional osteoblasts illustrates the volume of regulation factors that play a role in bone development (Table 3).
Comparatively to miRNA, long non-coding RNA (lncRNA) are longer transcripts of more than 200 nucleotides associated with gene regulation in many cellular processes, such as proliferation, differentiation and cancer development [142,143]. The function of this family of RNAs is not yet fully understood; however, they have been shown to regulate gene expression via assistance in transcription factor-promotor binding [144]. A novel lncRNA was identified that is able to regulate the fate of BMSC during aging, denoted Bmncr (bone marrow stem cell-related lncRNA) [112], promoting bone formation. Bmncr was found to be highly expressed in bone and adipose tissue, displaying a high expression in the BMSC of young mice, with a decrease in older mice. The deficiency of Bmncr produced a premature bone aging phenotype in a KO model, with the overexpression leading to increased bone density and reduced bone marrow fat. It was revealed that Bmncr upregulates the extracellular matrix molecular fibromodulin to anchor BMSC in trabecular-rich regions via activation of the BMP2 pathway. Furthermore, it was elucidated that Bmncr interacts with TAZ and ABL, facilitating the TAZ and RUNX2/PPARy transcriptional complex, further promoting osteogenesis whilst inhibiting adipogenesis in bone. These findings demonstrate that non-coding RNA species play important roles in bone development and have helped identify potential targets for the rescue of osteoporosis and other bone phenotypes, with a multitude of pathways and factors involved in these complex systems.
Table
Table 1. The key epigenetic modifications in MSC and their modes of gene regulation.
Table 1. The key epigenetic modifications in MSC and their modes of gene regulation.
Epigenetic ModificationMode of Gene RegulationReference
DNA MethylationDNA Modification (Cytosine/Adenine methylation)[66]
Histone MethylationHistone modification[85]
Histone AcetylationHistone modification[85]
miRNATargeting of mRNA[118]
Long non-coding RNATargeting transcription machinery[142]
Chromatin StructureAltered gene accessibility[54]
Table
Table 2. Summary of the key histone modifications related to function and abundance in aging MSC.
Table 2. Summary of the key histone modifications related to function and abundance in aging MSC.
Modification
(Function)		Writers/ErasersEffect of Aging on ModificationReference
Methylation
H3K27me3Ezh2 Decreased[87]
H3K9me3SUV39H1 Increased[74]
KDM-3A/4C [97]
KDM4B [100]
H3K36me3SETD2Decreased[98]
H3K4me3ASH1LDecreased
KDM5a
Acetylation
H3K9AcGCN5 Decreased[105]
HDAC9 [106]
H3K56AcSIRT6 Increased[109,110]
H3K14AcKAT7Increased[61,112]
Table
Table 3. Summary of miRNA implicated in MSC and skeletal tissue aging and development.
Table 3. Summary of miRNA implicated in MSC and skeletal tissue aging and development.
miRNAFunction and Pathways (Reference)
miR-29a-3pMaintenance of stem cell self-renewalSOD2 and DNMT3A[127]
miR-30c-5pInhibition[127]
miR-19a-3pInduction of OsteogenesisHDAC4 Inhibition[131]
miR-181a/b-1PI3/Akt[136]
miR-105Sox9[120]
miR-199Osteogenic InhibitionWnt Signalling[126]
miR-124FGFR1, JNK, p38[130]
miR376c-3pIGFR1/Akt[122]
miR-23aRunx2[124]
miR-30cRunx2[124]
miR-138Runx2/Osx[140]

4. The Role of Environmental Factors in MSC Aging and Disease

Type II diabetes mellitus (T2DM) is among the most common global chronic diseases, with a prevalence of 8.5% in adults [145]. The global rise in T2DM prevalence is allied with the obesity pandemic, which, in turn, is coupled with the consumptions of high-fat diets (HFD) [146]. The development of insulin insensitivity in people with obesity is associated with a higher prevalence of fragile bones due to osteoporosis and increased risk of major fractures [147]. Diets that are particularly high in saturated fat can negatively influence the bone mineralisation and skeletal integrity in both human and animal studies [148,149,150]. Interestingly, the fat quality seems to be as important as fat quantity in changing skeleton characteristics, where diets containing higher saturated fats have more adverse effects on bone development compared to those diets containing high levels of unsaturated fats [148,151].
Maternal obesity in mice caused by high-glucose/fat diets has been shown to compromise the skeletal health of dams and during foetal development and postnatal growth in offspring, increasing the risk of low bone mass in adulthood [152,153,154]. Furthermore, investigations of foetal MSC derived from the offspring of obese mothers in human and rodent studies showed increased cellular senescence signalling, with the overexpression of p53 as a hallmark of senescence associated with a significant reduction in glucose metabolism [155]. These findings implicate the role of the diet in altering MSC growth and properties via diet-mediated epigenetic changes during pregnancy.

4.1. Effect of Diet on Epigenetics in MSC

During prenatal and postnatal development, epigenetic modifications have a crucial role in regulating the fate of different cells. Diet controls the epigenetic regulations of gene expression. Offspring born to HFD-fed mothers have altered epigenetic regulation in bone development and formation. Various studies have shown the effect of maternal nutrition on the metabolism status of offspring, which mainly occurs through epigenetic alterations and the gene expression of key metabolic pathways, including glucose metabolism [71,87,156,157].
H3K27me3 has been shown to be a repressive epigenetic histone modification of RUNX2, the master transcriptional regulator of BMSC osteogenic differentiation [158]. Maternal obesity has been associated with an increase in the expression of senescence genes of osteoprogenitors through the acetylation of H3K27ac [159]. The expression of osteoblastogenesis-associated genes such as Pthlh and Col2α1 was synergistically decreased through significantly enriched H3K27me3 and H3K27ac in dams of HFD-fed maternal mice [160]. The diet has also been shown to influence the nutrition status of the cells, which provides different metabolites for epigenetic activities. For example, acetyl-coenzyme A, S-adenosylmethionine and nicotinamide adenine dinucleotide (NAD) are among many metabolites that are essential cofactors in histone methylation and/or acetylation affecting gene expression [161].
Diet and, more specifically, glucose implement their effects on bone formation through “the bone–pancreas loop”. Osteocalcin (OCN) is a major bone-specific protein secreted by osteoblasts in a carboxylated form. The acidic environment created by the maturation and activity of osteoclasts promotes the decarboxylation and activation of OCN and its release into the circulation. Upon binding to its receptors on pancreatic β cells, OCN triggers insulin release into the circulation. It stimulates β-cell proliferation and increases insulin sensitivity in liver, muscle and adipose tissue, in addition to its role as a metabolic hormone. Insulin binds to its receptors on osteoblasts (InsR) and increases the glucose uptake [162,163,164]. Insulin mainly controls OCN production by osteoblasts through two mechanisms. Firstly, by blocking the activity of Twist-2, an inhibitor of RUNX2, and driving OCN production. Secondly, by negatively controlling the activity of osteoclasts to increase the resorption of the bone matrix by creating a low pH environment [165,166]. Therefore, an endocrine feedforward loop is created between the bone and the pancreas, where insulin controls the activity of OCN while osteoblasts regulate insulin secretion from the pancreas via the release of OCN [167]. Thus, the negative correlation between the serum levels of uncarboxylated OCN and plasma glucose concentrations can be used as a measure of the osteoblast activity [168,169,170].
Studies of Ocn-deficient mice showed glucose intolerance, hyperglycaemia and diabetes-like characteristics in these mice [163]. Thus, it can be hypothesised that high blood glucose is potentially a cause of bone loss and bone disease. Various investigations have reported on the effects of HFD and T2DM on the quality of the bone and the development of osteoporosis [4,28,38,39,83]. Studies of BMSC derived from HFD-induced obesity and T2DM individuals reported a reduction in BMSC proliferation and osteogenic potential associated with increased apoptosis and low bone quality [4,41]. Moreover, a partial or fully inducible ablation of osteoblasts in mice led to insulin insensitivity and an increase in the blood glucose levels [42]. In addition, high glucose levels have been shown to direct BMSC towards an adipogenic fate rather than undergoing osteoblastic differentiation. While insulin insensitivity drives the reduction of osteoblasts numbers and bone formation in hyperglycaemic patients; the accumulation of lipid-dense adipocytes in the bone marrow of long bones also contributes to thinning of the cortical envelope, causing more fragile bones, akin to an osteoporotic phenotype [171]. Although high blood glucose levels are linked to a high fracture risk in metabolic patients such as diabetes, the epigenetic changes that occur in the skeletal tissue of these patients remain largely unknown.
A high protein intake is directly associated with a high bone density. The positive impact of a high protein intake on bones occurs through several mechanisms such as calcium absorption and IGF-1 secretion. However, the epigenetic role of a high-protein diet and HFD on the fate of MSC has yet to be fully investigated. Studies on both human and animal BMSC have demonstrated the essential role of protein intake on bone health during aging through regulation of the calcium balance and metabolism in the presence of both high and low-protein intakes [172]. Essential amino acids (AA) availability determines BMSC patterns of osteoblastic proliferation and differentiation. BMSC grown in a decreased AA concentration showed early senescence and cell death [173]. Whilst AA availability in low-protein intake (LPD) has been shown to impair bone mass during growth through IGF-I with age [174], there is little known about how LPD effects the overall bone health and BMSC fate differentiation in young adults [175]. Other studies of mouse maternal protein intakes have also shown to affect foetal bone formation and mineral quality; yet, these findings were gender-specific and inconsistent among all experimental groups [176]. Furthermore, it was reported that LPD caused an increased expression of DNA methyltransferases Dnmt1 and Dnmt3L [177], which may potentially act as a driver for regulating bone formation.

4.2. Effect of Diet on MSC during Aging

Caloric intake has a significant impact on stem cell self-renewal and lineage differentiation, as well as aging. While caloric restriction (CR) has been demonstrated to increase the lifespan, stemness and delay aging, HFD has been associated with the acceleration of aging in stem cell populations. In addition, the formation of ROS and DNA damage, as the result of HFD and the metabolic status, is also a major contributor to the acceleration of cellular senescence and the aging process. In contrast to HFD, CR has been reported to enhance stem cell function and decelerate cellular senescence in mouse HSC [178].
Obesity and aging are considered important intrinsic and extrinsic stressors that apply epigenetic effects on the gene expression of stem cells and alter their fate. Adult stem cells are capable of acquiring epigenetic memory from these stimuli over time. Aging is uniquely linked to the hypermethylation of CpG islands and hypomethylation of global DNA in all cell types [179,180]. One study identified the role of either aging or obesity in global DNA hypomethylation and the synergic effect of these two factors on lean and obese mice. The results confirmed that the global hypomethylation of adipose-derived stem cells occurs with aging, and the transcriptome remains extremely stable in lean mice, while obesity impairs this process [61]. Moreover, alterations in the cellular metabolic state as the result of aging claim to influence an organism’s stem cell lifespan and affect the activation of epigenetic enzymes with their availability.
The metabolic state plays a vital role in MSC function and survival. Age-associated changes in the MSC metabolic clock occur via mitochondrial dysfunction and accelerated anabolic signalling, causing an increase in the production and accumulation of ROS and cellular senescence [181,182]. In addition, recent reports have shown the effects of cellular metabolism on epigenetic states and organism aging [183,184]. It was observed that NAD+ levels, a cofactor of Sirtuins (SIRT1–7) deacetylases, decreases with age, causing a reduction in cellular histone acetylation [185,186]. As MSCs reside within a hypoxic environment, glycolysis is the major source of energy production, with a low ROS production at a steady rate [187,188]. Proliferation and aging shift the MSC metabolism towards oxidative phosphorylation, which drives the cellular senescence by increasing the ROS level and oxidative stress [189]. Higher levels of ROS damage the protein and DNA, especially at telomeric regions. This is in parallel with the decrease in SIRT1, which, in turn, impedes FOXO1, a transcription factor regulating antioxidant expression, deacetylation and repress antioxidant machinery [183,190].
NAD is also a cofactor of histone modifiers, including H3K4me3, H3K36me3 and H3K27me3, influencing epigenomic regulation [105,183]. Furthermore, BMSC of aged donors have been shown to have a lower expression of Hox genes as a regulator of DNA methylation. Consequently, DNA was hypomethylated, changing the differentiation and regeneration potential of these cells [27,191].

4.3. Mechanical Loading Effects on MSC

Exercise or mechanical loading is a key factor in improving the general body health through balancing metabolism and cardiovascular functions, as well as promoting good skeletal health. Physical activity can prevent bone deterioration by antagonising RANKL signalling, leading to decreased bone resorption by OC and increasing bone formation and strength with reduced adiposity in the marrow cavity [192,193,194]. A number of studies have also reported how the mechanical stimulation of BMSC leads to reductions in adipose formation and upregulation of osteogenesis via increased levels of osteoblastic markers such as RUNX2 [164,195,196,197,198,199,200,201]. Conversely, bone formation was reduced and osteoclast activity was enhanced during inactivity [202].
The effect of mechanical force on BMSC gene expression profiles through epigenetic modifications has been explored in recent years. Actin polymerisation has been shown to regulate epigenetic gene regulation by changing the physical shape of nuclei, which affects specific signal transduction [203]. Moreover, mechanical force appears to drive BMSC differentiation towards the osteoblastic lineage, in part through the induction of non-coding RNA, such as lncRNA-MEG3 [104]. According to another similar study, miRNA-103A and its host gene PANK3 are downregulated following mechanical stimulation in BMSC, which stimulates the expression of the Runx2 protein [204]. In addition, the result of a study on human BMSC showed the elevation of bone growth under mechanical stress due to the reduction of DNA methylation of osteogenic genes, causing an increase in expression [205]. Furthermore, the analysis of human skeletal muscle showed alterations in methylation at 4919 sites of DNA following exercise [206]. Similar reports described that DNA methylation was altered in a genome-wide manner in human fat tissue following exercise, linking exercise with the epigenetic regulation of adipocyte metabolism [207]. Similar reports described that DNA methylation was altered in a genome-wide manner in human fat tissue following exercise, linking exercise with the epigenetic regulation of adipocyte metabolism. One study found that, following exercise, 17,975 individual CpG sites showed differential DNA methylation in adipose tissue. Several of these genes have been previously associated with obesity and T2D [207].
The effect of a running exercise was further investigated in osteoporotic patients and in an ovariectomised mouse model of osteoporosis. The findings identified nuclear factor erythroid-derived 2-related factor-2 (Nrf2) as a critical anti-osteoporotic factor that was heavily suppressed by the activity of DNMT in its promoter. This study claimed that a running exercise could correct the effect of DNMT hypermethylation of the Nrf2 promotor, making this epigenetic feature a potential target of the pathogenesis of osteoporosis [204].
It has also been proposed that exercise can control bone formation through epigenetics by regulating inflammation and triggering changes in the gene expression patterns of neutrophils and peripheral blood mononuclear cells, which can lead to the inhibition of bone resorption [208]. Another study examined the effect of physical activity on the methylation of human apoptosis-associated speck-like protein (ASC), a p53-target gene that regulates the p53-Bax mitochondrial apoptotic pathway and is linked to IL-1β and IL-18 secretion [209]. IL-1β and IL-18 are proinflammatory cytokines that have a prominent role in the development and progression of several age- and inactivity-related diseases. The role of aging and exercise on CpG island methylation of the ASC gene revealed that, although the expression on the ASC gene is upregulated by age, six months of intermittent walking reduced ASC expression by increasing DNA methylation, which consequently lowered the level of proinflammatory cytokines [209]. Therefore, it appears that environmental and endogenous cues alter the gene expression pattern and, ultimately, the fate of BMSC through epigenetic regulation. Considering the reversible nature of epigenetic changes, modification of the MSC epigenetic landscape via physical training or external stimuli may be an appropriate target for reprograming MSC gene expression to improve cell survival and function.

5. Conclusions

The information theory of aging relates to the erosion of the epigenetic landscape as cells age. This contributes to the deregulated function of cells and their loss of identity. Investigation of the epigenetic changes in MSC as they age over the years has demonstrated dynamic changes in DNA methylation, hydroxymethylation, histone modifications and non-coding RNA. These changes result in senescence, skewed differentiation favouring adipogenesis at the expense of osteogenesis and the loss of heterochromatin. The chromatin structure is now recognised as an important guardian of the genome and a transducer of epigenetic information that is altered during aging, where MSCs have a higher level of accessible chromatin compared to somatic cells to ensure plasticity. Interestingly, MSCs show remarkable nucleosome position stability as they age, with changes occurring along stress response genes to ensure protective mechanisms are in place. Changes in the chromatin structure and suppression of stemness genes through decreased chromatin accessibility, especially along differentiation genes enriched for bivalent chromatin domains, drive MSC aging. The advantage of assessing chromatin accessibility is amplified with the discovery that chromatin changes seem to occur in regions with identified SNPs for multiple diseases, including obesity, immunity and bone-related disorders, emphasising another level of exploration for potential therapeutic targets to counter stem cell aging and disease.
Histone and DNA modifications are the key mediators of the chromatin structure and genomic regions associated with MSC age-related increases in DNA methylation in association with repressive histone marks H3K27me3 and H3K9me3, which also appear to play important roles during osteoporosis. Of note, Ezh2 has been shown to deposit H3K27me3 on bone-associated genes in MSC derived from osteoporotic samples, as well as deactivate the antioxidant defence system, reducing osteogenesis. Interestingly, supplementing antioxidants or inhibiting Ezh2 can reverse the effects on aging MSC and restore differentiation. Moreover, the H3K9me3 levels also increase during MSC aging, and loss of the H3K9me3 demethylase KDM4B results in repression of the osteogenic-related genes, increased MSC senescence and accelerated aging. Many studies have confirmed a global decrease in H3 and H4 acetylation mainly due to an increase in HDAC4, 5 and 6, resulting in a decrease in stemness gene expression and self-renewal. In particular, H3K9 acetylation decreases during aging and is associated with the decreased expression of Wnt, Bmp genes and Runx2, compromising MSC osteogenesis and autophagy. HDAC1 and 2, on the other hand, increase in expression, leading to increased p16 expression and MSC senescence. These examples illustrate how the erosion of the epigenetic landscape alters transcription at multiple levels in aging MSC.
The additional layer of epigenetic modifiers in the form of miRNA and long non-coding RNA has also advanced considerably in recent times, as they have been shown to be deregulated in aged MSC. As highlighted in this review, miRNAs are able to regulate the factors involved in DNA methylation, as well as histone methylation/acetylation, imposing a broad range of control over the changing epigenetic landscape within aging MSC. Further works into elucidating the roles of different miRNA species and implicating them in not only aging but many different diseases will provide a greater insight into the ever-evolving epigenetic landscape.
Given the influence the environment has on our epigenome, future studies will increase dramatically, showing how diet and lifestyle affects the epigenetic drift and aging. Studies on high-fat/sugar diets have recently shown that a high-fat maternal diet can compromise the skeletal integrity of offspring, giving rise to low bone mass. MSC display senescence, reduced osteogenesis, increased adipogenesis and reduced glucose metabolism. Increased H3K27Ac on senescent genes and the repressive H3K27me3 on osteogenic genes, together with DNA methylation changes, drive senescence and inhibit osteogenesis. Further studies are needed to examine the plethora of histone and DNA modification changes in response to different diets and the effects of different metabolites that act as cofactors for epigenetic enzymes. One of the most effective treatments for bone loss is mechanical loading and resistance exercise, which has shown to result in reduced DNA methylation along osteogenic genes and the expression of long non-coding RNA species, enhancing osteogenesis. The information instructing the chromatin architecture and, therefore, cellular function and longevity is complex and interdependent. Just how all these layers change and contribute to aging represents a field that is now rapidly expanding with an effort to reboot the epigenetic code safely as a strategy to rejuvenate stem cells.

Author Contributions

Conceptualisation, N.S., S.S., D.C. and S.G.; investigation, N.S., S.S., D.C. and S.G.; resources, D.C. and S.G.; writing—original draft preparation, N.S., S.S., D.C. and S.G.; writing—review and editing, N.S., S.S., D.C. and S.G.; supervision, D.C. and S.G.; project administration, D.C. and S.G. and funding acquisition, D.C. and S.G. All authors have read and agreed to the published version of the manuscript.

Funding

This review was funded in part by The National Health and Medical Research Council Australia, project grant APP1141361, Medical Research Fund grant APP2007554 and Higher Degree Research and International Scholarships with stipends, University of Adelaide.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

All figures were created with BioRender.com.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

3′UTR3′ Untranslated Region
5′UTR5′ Untranslated Region
5mC5-Methylcytosine
5hmC5-Hydroxymethylcytosine
AAAmino acids
AMSCAdipose-derived MSC
ALPAlkaline phosphatase
ASCApoptosis-associated speck-like protein
ATAC-seqAssay for transposase—accessible chromatin with high-throughput sequencing
BMSCBone Marrow Stromal Cells
BMPBone Morphogenic Protein
BRMBrahma
Brg-1Brahma-related gene 1
CRCaloric Restriction
ChIPChromatin Immunoprecipitation
ColIαICollagen-Iα
CFU-FColony-Forming Unit—Fibroblasts
CpGCytosine-phospho-Guanine
DNMTDNA Methyl Transferase
ESCEmbryonic Stem cells
Ezh2Enhancer of Zeste
HDACHistone Deacetylase
H3K14AcHistone 3 lysine 14 acetylation
H3K27me3Histone 3 lysine 27 tri-methylation
HSCHaematopoietic Stem cells
HFDHigh-Fat Diet
GCN5General control nonderepressible 5
GOGene ontology
LPDLow protein uptake
METTL3Methyl transferase-like 3
MSCMesenchymal Stromal Cells
NAP1L2Nucleosome assembly protein 1-like 2
N6-mAN6-methyladenosine
Nrf22-related factor-2
OPNOsteopontin
OCNOsteocalcin
OPGOsteoprotegrin
PCAFp300/CBP-associated factor
PGCPolycomb Group Complex
PRC1Polycomb repressive complex 1
RANKReceptor Activator of Nuclear Factor-kappa B
RANKLRANK-Ligand
ROSReactive Oxygen Species
Runx2Runt-related Transcription factor 2
Sirtuins1-7SIRT1-7
SOSTSclerostin
SNPSingle-Nucleotide Polymorphism
TSSTranscription Start Site
ZKSCAN3Zinc finger protein with KRAB and SCAN domains 3

References

  1. Knight, M.N.; Hankenson, K.D. Mesenchymal Stem Cells in Bone Regeneration. Adv. Wound Care 2013, 2, 306–316. [Google Scholar] [CrossRef] [Green Version]
  2. Friedenstein, A.J.; Chailakhyan, R.K.; Latsinik, N.V.; Panasyuk, A.F.; Keiliss-Borok, I.V. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974, 17, 331–340. [Google Scholar] [CrossRef]
  3. Castro-Malaspina, H.; Gay, R.E.; Resnick, G.; Kapoor, N.; Meyers, P.; Chiarieri, D.; McKenzie, S.; Broxmeyer, H.E.; Moore, M.A. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 1980, 56, 289–301. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Merryweather-Clarke, A.T.; Cook, D.; Lara, B.J.; Hua, P.; Repapi, E.; Ashley, N.; Lim, S.Y.; Watt, S.M. Does osteogenic potential of clonal human bone marrow mesenchymal stem/stromal cells correlate with their vascular supportive ability? Stem Cell Res. Ther. 2018, 9, 351. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Gronthos, S.; Zannettino, A.C.; Hay, S.J.; Shi, S.; Graves, S.E.; Kortesidis, A.; Simmons, P.J. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J. Cell Sci. 2003, 116 Pt 9, 1827–1835. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Sacchetti, B.; Funari, A.; Michienzi, S.; Di Cesare, S.; Piersanti, S.; Saggio, I.; Tagliafico, E.; Ferrari, S.; Robey, P.G.; Riminucci, M.; et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007, 131, 324–336. [Google Scholar] [CrossRef] [Green Version]
  7. Wada, T.; Ishimoto, Y.; Hirosaki, M.; Konno, A.; Kasahara, Y.; Kimura, Y.; Nakatsuka, H.; Sakamoto, R.; Ishine, M.; Okumiya, K.; et al. Twenty-one-item fall risk index predicts falls in elderly community-dwelling Japanese. J. Am. Geriatr. Soc. 2009, 57, 2369–2371. [Google Scholar] [CrossRef]
  8. Garcia Santos, J.M.; Inuggi, A.; Gomez Espuch, J.; Vazquez, C.; Iniesta, F.; Blanquer, M.; Maria Moraleda, J.; Martinez, S. Spinal cord infusion of stem cells in amyotrophic lateral sclerosis: Magnetic resonance spectroscopy shows metabolite improvement in the precentral gyrus. Cytotherapy 2016, 18, 785–796. [Google Scholar] [CrossRef]
  9. Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D.; Moorman, M.A.; Simonetti, D.W.; Craig, S.; Marshak, D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284, 143–147. [Google Scholar] [CrossRef] [Green Version]
  10. Shi, S.; Gronthos, S. Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J. Bone Miner Res. 2003, 18, 696–704. [Google Scholar] [CrossRef] [Green Version]
  11. Gronthos, S.; Simmons, P.J.; Graves, S.E.; Robey, P.G. Integrin-mediated interactions between human bone marrow stromal precursor cells and the extracellular matrix. Bone 2001, 28, 174–181. [Google Scholar] [CrossRef] [PubMed]
  12. Alsalameh, S.; Amin, R.; Gemba, T.; Lotz, M. Identification of mesenchymal progenitor cells in normal and osteoarthritic human articular cartilage. Arthritis Rheum. 2004, 50, 1522–1532. [Google Scholar] [CrossRef]
  13. Gronthos, S.; Simmons, P.J. The growth factor requirements of STRO-1-positive human bone marrow stromal precursors under serum-deprived conditions in vitro. Blood 1995, 85, 929–940. [Google Scholar] [CrossRef] [Green Version]
  14. Logan, M.; Martin, J.F.; Nagy, A.; Lobe, C.; Olson, E.N.; Tabin, C.J. Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis 2002, 33, 77–80. [Google Scholar] [CrossRef] [PubMed]
  15. Kalajzic, Z.; Li, H.; Wang, L.P.; Jiang, X.; Lamothe, K.; Adams, D.J.; Aguila, H.L.; Rowe, D.W.; Kalajzic, I. Use of an alpha-smooth muscle actin GFP reporter to identify an osteoprogenitor population. Bone 2008, 43, 501–510. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Mendez-Ferrer, S.; Michurina, T.V.; Ferraro, F.; Mazloom, A.R.; Macarthur, B.D.; Lira, S.A.; Scadden, D.T.; Ma’ayan, A.; Enikolopov, G.N.; Frenette, P.S. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466, 829–834. [Google Scholar] [CrossRef] [Green Version]
  17. Park, D.; Spencer, J.A.; Koh, B.I.; Kobayashi, T.; Fujisaki, J.; Clemens, T.L.; Lin, C.P.; Kronenberg, H.M.; Scadden, D.T. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell 2012, 10, 259–272. [Google Scholar] [CrossRef] [Green Version]
  18. Zhou, B.O.; Yue, R.; Murphy, M.M.; Peyer, J.G.; Morrison, S.J. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 2014, 15, 154–168. [Google Scholar] [CrossRef] [Green Version]
  19. Greenbaum, A.; Hsu, Y.M.; Day, R.B.; Schuettpelz, L.G.; Christopher, M.J.; Borgerding, J.N.; Nagasawa, T.; Link, D.C. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 2013, 495, 227–230. [Google Scholar] [CrossRef] [Green Version]
  20. Zannettino, A.C.; Paton, S.; Kortesidis, A.; Khor, F.; Itescu, S.; Gronthos, S. Human mulipotential mesenchymal/stromal stem cells are derived from a discrete subpopulation of STRO-1bright/CD34 /CD45(-)/glycophorin-A-bone marrow cells. Haematologica 2007, 92, 1707–1708. [Google Scholar] [CrossRef] [Green Version]
  21. Chan, C.K.; Seo, E.Y.; Chen, J.Y.; Lo, D.; McArdle, A.; Sinha, R.; Tevlin, R.; Seita, J.; Vincent-Tompkins, J.; Wearda, T.; et al. Identification and specification of the mouse skeletal stem cell. Cell 2015, 160, 285–298. [Google Scholar] [CrossRef] [Green Version]
  22. Worthley, D.L.; Churchill, M.; Compton, J.T.; Tailor, Y.; Rao, M.; Si, Y.; Levin, D.; Schwartz, M.G.; Uygur, A.; Hayakawa, Y.; et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell 2015, 160, 269–284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Zannettino, A.C.; Paton, S.; Arthur, A.; Khor, F.; Itescu, S.; Gimble, J.M.; Gronthos, S. Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivo. J. Cell Physiol. 2008, 214, 413–421. [Google Scholar] [CrossRef] [PubMed]
  24. Gronthos, S.; Mankani, M.; Brahim, J.; Robey, P.G.; Shi, S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2000, 97, 13625–13630. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Kuznetsov, S.A.; Mankani, M.H.; Gronthos, S.; Satomura, K.; Bianco, P.; Robey, P.G. Circulating skeletal stem cells. J. Cell Biol. 2001, 153, 1133–1140. [Google Scholar] [CrossRef] [Green Version]
  26. Seo, B.M.; Miura, M.; Gronthos, S.; Bartold, P.M.; Batouli, S.; Brahim, J.; Young, M.; Robey, P.G.; Wang, C.Y.; Shi, S. Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet 2004, 364, 149–155. [Google Scholar] [CrossRef]
  27. Cakouros, D.; Gronthos, S. The changing epigenetic landscape of Mesenchymal Stem/Stromal Cells during aging. Bone 2020, 137, 115440. [Google Scholar] [CrossRef]
  28. Marie, P.J. Bone cell senescence: Mechanisms and perspectives. J. Bone Miner Res. 2014, 29, 1311–1321. [Google Scholar] [CrossRef]
  29. Reyes, M.; Lund, T.; Lenvik, T.; Aguiar, D.; Koodie, L.; Verfaillie, C.M. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001, 98, 2615–2625. [Google Scholar] [CrossRef]
  30. Marsh, D. Concepts of fracture union, delayed union, and nonunion. Clin. Orthop. Relat. Res. 1998, 355S, S22–S30. [Google Scholar] [CrossRef]
  31. Arthur, A.; Zannettino, A.; Gronthos, S. The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. J. Cell Physiol. 2009, 218, 237–245. [Google Scholar] [CrossRef] [PubMed]
  32. Lyles, K.W.; Colon-Emeric, C.S.; Magaziner, J.S.; Adachi, J.D.; Pieper, C.F.; Mautalen, C.; Hyldstrup, L.; Recknor, C.; Nordsletten, L.; Moore, K.A.; et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 2007, 357, 1799–1809. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Niccoli, T.; Partridge, L. Ageing as a risk factor for disease. Curr. Biol. 2012, 22, R741–R752. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Cai, G.-P.; Liu, Y.-L.; Luo, L.-P.; Xiao, Y.; Jiang, T.-J.; Yuan, J.; Wang, M. Alkbh1-mediated DNA N6-methyladenine modification regulates bone marrow mesenchymal stem cell fate during skeletal aging. Cell Prolif. 2022, 55, e13178. [Google Scholar] [CrossRef]
  35. Zupan, J.; Strazar, K.; Kocijan, R.; Nau, T.; Grillari, J.; Marolt Presen, D. Age-related alterations and senescence of mesenchymal stromal cells: Implications for regenerative treatments of bones and joints. Mech. Ageing Dev. 2021, 198, 111539. [Google Scholar] [CrossRef]
  36. Loeser, R.F. Aging and osteoarthritis. Curr. Opin. Rheumatol. 2011, 23, 492–496. [Google Scholar] [CrossRef] [Green Version]
  37. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285, 785–795. [Google Scholar] [CrossRef]
  38. Kassem, M.; Marie, P.J. Senescence-associated intrinsic mechanisms of osteoblast dysfunctions. Aging Cell 2011, 10, 191–197. [Google Scholar] [CrossRef]
  39. Meng, Q.S.; Liu, J.; Wei, L.; Fan, H.M.; Zhou, X.H.; Liang, X.T. Senescent mesenchymal stem/stromal cells and restoring their cellular functions. World J. Stem Cells 2020, 12, 966–985. [Google Scholar] [CrossRef]
  40. Yu, J.; Shi, J.; Zhang, Y.; Zhang, Y.; Huang, Y.; Chen, Z.; Yang, J. The replicative senescent mesenchymal stem / stromal cells defect in DNA damage response and anti-oxidative capacity. Int. J. Med. Sci. 2018, 15, 771–781. [Google Scholar] [CrossRef] [Green Version]
  41. Nehlin, J.O.; Jafari, A.; Tencerova, M.; Kassem, M. Aging and lineage allocation changes of bone marrow skeletal (stromal) stem cells. Bone 2019, 123, 265–273. [Google Scholar] [CrossRef] [Green Version]
  42. Boskey, A.L.; Coleman, R. Aging and bone. J. Dent. Res. 2010, 89, 1333–1348. [Google Scholar] [CrossRef] [PubMed]
  43. Burr, D.B. Changes in bone matrix properties with aging. Bone 2019, 120, 85–93. [Google Scholar] [CrossRef] [PubMed]
  44. Guang, L.G.; Boskey, A.L.; Zhu, W. Age-related CXC chemokine receptor-4-deficiency impairs osteogenic differentiation potency of mouse bone marrow mesenchymal stromal stem cells. Int. J. Biochem. Cell Biol. 2013, 45, 1813–1820. [Google Scholar] [CrossRef] [PubMed]
  45. Kanawa, M.; Igarashi, A.; Ronald, V.S.; Higashi, Y.; Kurihara, H.; Sugiyama, M.; Saskianti, T.; Pan, H.; Kato, Y. Age-dependent decrease in the chondrogenic potential of human bone marrow mesenchymal stromal cells expanded with fibroblast growth factor-2. Cytotherapy 2013, 15, 1062–1072. [Google Scholar] [CrossRef] [PubMed]
  46. Zhou, S.; Greenberger, J.S.; Epperly, M.W.; Goff, J.P.; Adler, C.; Leboff, M.S.; Glowacki, J. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell 2008, 7, 335–343. [Google Scholar] [CrossRef] [Green Version]
  47. Kim, M.; Kim, C.; Choi, Y.S.; Kim, M.; Park, C.; Suh, Y. Age-related alterations in mesenchymal stem cells related to shift in differentiation from osteogenic to adipogenic potential: Implication to age-associated bone diseases and defects. Mech. Ageing Dev. 2012, 133, 215–225. [Google Scholar] [CrossRef] [PubMed]
  48. Corrado, A.; Cici, D.; Rotondo, C.; Maruotti, N.; Cantatore, F.P. Molecular Basis of Bone Aging. Int. J. Mol. Sci. 2020, 21, 3679. [Google Scholar] [CrossRef] [PubMed]
  49. Gnani, D.; Crippa, S.; Della Volpe, L.; Rossella, V.; Conti, A.; Lettera, E.; Rivis, S.; Ometti, M.; Fraschini, G.; Bernardo, M.E.; et al. An early-senescence state in aged mesenchymal stromal cells contributes to hematopoietic stem and progenitor cell clonogenic impairment through the activation of a pro-inflammatory program. Aging Cell 2019, 18, e12933. [Google Scholar] [CrossRef] [Green Version]
  50. Siegel, G.; Kluba, T.; Hermanutz-Klein, U.; Bieback, K.; Northoff, H.; Schafer, R. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med. 2013, 11, 146. [Google Scholar] [CrossRef] [Green Version]
  51. Franceschi, C.; Bonafe, M.; Valensin, S.; Olivieri, F.; De Luca, M.; Ottaviani, E.; De Benedictis, G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 2000, 908, 244–254. [Google Scholar] [CrossRef]
  52. Franceschi, C.; Garagnani, P.; Parini, P.; Giuliani, C.; Santoro, A. Inflammaging: A new immune-metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 2018, 14, 576–590. [Google Scholar] [CrossRef]
  53. Josephson, A.M.; Bradaschia-Correa, V.; Lee, S.; Leclerc, K.; Patel, K.S.; Muinos Lopez, E.; Litwa, H.P.; Neibart, S.S.; Kadiyala, M.; Wong, M.Z.; et al. Age-related inflammation triggers skeletal stem/progenitor cell dysfunction. Proc. Natl. Acad. Sci. USA 2019, 116, 6995–7004. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Hamilton, J.P. Epigenetics: Principles and practice. Dig. Dis. 2011, 29, 130–135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Shan, X.; Roberts, C.; Lan, Y.; Percec, I. Age Alters Chromatin Structure and Expression of SUMO Proteins under Stress Conditions in Human Adipose-Derived Stem Cells. Sci. Rep. 2018, 8, 11502. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. de la Serna, I.L.; Ohkawa, Y.; Imbalzano, A.N. Chromatin remodelling in mammalian differentiation: Lessons from ATP-dependent remodellers. Nat. Rev. Genet. 2006, 7, 461–473. [Google Scholar] [CrossRef]
  57. Hendricks, K.B.; Shanahan, F.; Lees, E. Role for BRG1 in cell cycle control and tumor suppression. Mol. Cell Biol. 2004, 24, 362–376. [Google Scholar] [CrossRef] [Green Version]
  58. Squillaro, T.; Severino, V.; Alessio, N.; Farina, A.; Di Bernardo, G.; Cipollaro, M.; Peluso, G.; Chambery, A.; Galderisi, U. De-regulated expression of the BRG1 chromatin remodeling factor in bone marrow mesenchymal stromal cells induces senescence associated with the silencing of NANOG and changes in the levels of chromatin proteins. Cell Cycle 2015, 14, 1315–1326. [Google Scholar] [CrossRef]
  59. Alessio, N.; Squillaro, T.; Cipollaro, M.; Bagella, L.; Giordano, A.; Galderisi, U. The BRG1 ATPase of chromatin remodeling complexes is involved in modulation of mesenchymal stem cell senescence through RB-P53 pathways. Oncogene 2010, 29, 5452–5463. [Google Scholar] [CrossRef] [Green Version]
  60. Ren, X.; Hu, B.; Song, M.; Ding, Z.; Dang, Y.; Liu, Z.; Zhang, W.; Ji, Q.; Ren, R.; Ding, J.; et al. Maintenance of Nucleolar Homeostasis by CBX4 Alleviates Senescence and Osteoarthritis. Cell Rep. 2019, 26, 3643–3656.e3647. [Google Scholar] [CrossRef] [Green Version]
  61. Hu, M.; Xing, L.; Zhang, L.; Liu, F.; Wang, S.; Xie, Y.; Wang, J.; Jiang, H.; Guo, J.; Li, X.; et al. NAP1L2 drives mesenchymal stem cell senescence and suppresses osteogenic differentiation. Aging Cell 2022, 21, e13551. [Google Scholar] [CrossRef] [PubMed]
  62. Pouikli, A.; Tessarz, P. Metabolism and chromatin: A dynamic duo that regulates development and ageing: Elucidating the metabolism-chromatin axis in bone-marrow mesenchymal stem cell fate decisions. Bioessays 2021, 43, e2000273. [Google Scholar] [CrossRef]
  63. Hu, H.; Ji, Q.; Song, M.; Ren, J.; Liu, Z.; Wang, Z.; Liu, X.; Yan, K.; Hu, J.; Jing, Y.; et al. ZKSCAN3 counteracts cellular senescence by stabilizing heterochromatin. Nucleic. Acids Res. 2020, 48, 6001–6018. [Google Scholar] [CrossRef] [PubMed]
  64. Lai, M.C.; Ruiz-Velasco, M.; Arnold, C.; Sigalova, O.; Bunina, D.; Berest, I.; Ding, X.; Hennrich, M.L.; Poisa-Beiro, L.; Claringbould, A.; et al. Enhancer-priming in ageing human bone marrow mesenchymal stromal cells contributes to immune traits. bioRxiv 2021. [Google Scholar] [CrossRef]
  65. Cakouros, D.; Gronthos, S. Epigenetic Regulation of Bone Marrow Stem Cell Aging: Revealing Epigenetic Signatures associated with Hematopoietic and Mesenchymal Stem Cell Aging. Aging Dis. 2019, 10, 174–189. [Google Scholar] [CrossRef] [Green Version]
  66. Moore, L.D.; Le, T.; Fan, G. DNA methylation and its basic function. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2013, 38, 23–38. [Google Scholar] [CrossRef] [Green Version]
  67. Cakouros, D.; Hemming, S.; Gronthos, K.; Liu, R.; Zannettino, A.; Shi, S.; Gronthos, S. Specific functions of TET1 and TET2 in regulating mesenchymal cell lineage determination. Epigenetics Chromatin 2019, 12, 3. [Google Scholar] [CrossRef]
  68. Smith, Z.D.; Meissner, A. DNA methylation: Roles in mammalian development. Nat. Rev. Genet. 2013, 14, 204–220. [Google Scholar] [CrossRef]
  69. Xu, L.; Liu, Y.; Sun, Y.; Wang, B.; Xiong, Y.; Lin, W.; Wei, Q.; Wang, H.; He, W.; Wang, B.; et al. Tissue source determines the differentiation potentials of mesenchymal stem cells: A comparative study of human mesenchymal stem cells from bone marrow and adipose tissue. Stem Cell Res. Ther. 2017, 8, 275. [Google Scholar] [CrossRef] [Green Version]
  70. Dawlaty, M.M.; Breiling, A.; Le, T.; Raddatz, G.; Barrasa, M.I.; Cheng, A.W.; Gao, Q.; Powell, B.E.; Li, Z.; Xu, M.; et al. Combined Deficiency of Tet1 and Tet2 Causes Epigenetic Abnormalities but Is Compatible with Postnatal Development.(Report). Dev. Cell 2013, 24, 310. [Google Scholar] [CrossRef] [Green Version]
  71. Li, C.J.; Xiao, Y.; Yang, M.; Su, T.; Sun, X.; Guo, Q.; Huang, Y.; Luo, X.H. Long noncoding RNA Bmncr regulates mesenchymal stem cell fate during skeletal aging. J. Clin. Investig. 2018, 128, 5251–5266. [Google Scholar] [CrossRef] [Green Version]
  72. Costa, Y.; Ding, J.; Theunissen, T.W.; Faiola, F.; Hore, T.A.; Shliaha, P.V.; Fidalgo, M.; Saunders, A.; Lawrence, M.; Dietmann, S.; et al. NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature 2013, 495, 370–374. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Chandru, A.; Bate, N.; Vuister, G.W.; Cowley, S.M. Sin3A recruits Tet1 to the PAH1 domain via a highly conserved Sin3-Interaction Domain. Sci. Rep. 2018, 8, 14689. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Baker, D.J.; Wijshake, T.; Tchkonia, T.; LeBrasseur, N.K.; Childs, B.G.; van de Sluis, B.; Kirkland, J.L.; van Deursen, J.M. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011, 479, 232–236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Deng, P.; Yuan, Q.; Cheng, Y.; Li, J.; Liu, Z.; Liu, Y.; Li, Y.; Su, T.; Wang, J.; Salvo, M.E.; et al. Loss of KDM4B exacerbates bone-fat imbalance and mesenchymal stromal cell exhaustion in skeletal aging. Cell Stem Cell 2021, 28, 1057–1073.e1057. [Google Scholar] [CrossRef] [PubMed]
  76. Yan, G.; Yuan, Y.; He, M.; Gong, R.; Lei, H.; Zhou, H.; Wang, W.; Du, W.; Ma, T.; Liu, S.; et al. m6A Methylation of Precursor-miR-320/RUNX2 Controls Osteogenic Potential of Bone Marrow-Derived Mesenchymal Stem Cells. Mol. Ther.-Nucleic Acids 2020, 19, 421–436. [Google Scholar] [CrossRef]
  77. Loots, G.G.; Kneissel, M.; Keller, H.; Baptist, M.; Chang, J.; Collette, N.M.; Ovcharenko, D.; Plajzer-Frick, I.; Rubin, E.M. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005, 15, 928–935. [Google Scholar] [CrossRef] [Green Version]
  78. Lewiecki, E.M. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther. Adv. Musculoskelet Dis. 2014, 6, 48–57. [Google Scholar] [CrossRef] [Green Version]
  79. Reppe, S.; Noer, A.; Grimholt, R.M.; Halldórsson, B.V.; Medina-Gomez, C.; Gautvik, V.T.; Olstad, O.K.; Berg, J.P.; Datta, H.; Estrada, K.; et al. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women. J. Bone Miner Res. 2015, 30, 249–256. [Google Scholar] [CrossRef]
  80. Lhaneche, L.; Hald, J.D.; Domingues, A.; Hannouche, D.; Delepine, M.; Zelenika, D.; Boland, A.; Ostertag, A.; Cohen-Solal, M.; Langdahl, B.L.; et al. Variations of SOST mRNA expression in human bone are associated with DNA polymorphism and DNA methylation in the SOST gene. Bone 2016, 92, 107–115. [Google Scholar] [CrossRef]
  81. Li, X.; Zhang, Y.; Kang, H.; Liu, W.; Liu, P.; Zhang, J.; Harris, S.E.; Wu, D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 2005, 280, 19883–19887. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  82. Delgado-Calle, J.; Sañudo, C.; Bolado, A.; Fernández, A.F.; Arozamena, J.; Pascual-Carra, M.A.; Rodriguez-Rey, J.C.; Fraga, M.F.; Bonewald, L.; Riancho, J.A. DNA methylation contributes to the regulation of sclerostin expression in human osteocytes. J. Bone Miner. Res. 2012, 27, 926–937. [Google Scholar] [CrossRef]
  83. Shan, Y.; Wang, L.; Li, G.; Shen, G.; Zhang, P.; Xu, Y. Methylation of bone SOST impairs SP7, RUNX2, and ERα transactivation in patients with postmenopausal osteoporosis. Biochem. Cell Biol. 2019, 97, 369–374. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Wang, P.; Cao, Y.; Zhan, D.; Wang, D.; Wang, B.; Liu, Y.; Li, G.; He, W.; Wang, H.; Xu, L. Influence of DNA methylation on the expression of OPG/RANKL in primary osteoporosis. Int. J. Med. Sci. 2018, 15, 1480–1485. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Sidler, C.; Woycicki, R.; Li, D.; Wang, B.; Kovalchuk, I.; Kovalchuk, O. A role for SUV39H1-mediated H3K9 trimethylation in the control of genome stability and senescence in WI38 human diploid lung fibroblasts. Aging 2014, 6, 545–563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  86. Zhang, Y.; Sun, Z.; Jia, J.; Du, T.; Zhang, N.; Tang, Y.; Fang, Y.; Fang, D. Overview of Histone Modification. Adv. Exp. Med. Biol. 2021, 1283, 1–16. [Google Scholar] [CrossRef] [PubMed]
  87. Bernstein, B.E.; Mikkelsen, T.S.; Xie, X.; Kamal, M.; Huebert, D.J.; Cuff, J.; Fry, B.; Meissner, A.; Wernig, M.; Plath, K.; et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125, 315–326. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  88. Ye, L.; Fan, Z.; Yu, B.; Chang, J.; Al Hezaimi, K.; Zhou, X.; Park, N.H.; Wang, C.Y. Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs. Cell Stem Cell 2012, 11, 50–61. [Google Scholar] [CrossRef] [Green Version]
  89. Jing, H.; Liao, L.; An, Y.; Su, X.; Liu, S.; Shuai, Y.; Zhang, X.; Jin, Y. Suppression of EZH2 Prevents the Shift of Osteoporotic MSC Fate to Adipocyte and Enhances Bone Formation During Osteoporosis. Mol. Ther. 2016, 24, 217–229. [Google Scholar] [CrossRef] [Green Version]
  90. Cakouros, D.; Isenmann, S.; Cooper, L.; Zannettino, A.; Anderson, P.; Glackin, C.; Gronthos, S. Twist-1 induces Ezh2 recruitment regulating histone methylation along the Ink4A/Arf locus in mesenchymal stem cells. Mol. Cell Biol. 2012, 32, 1433–1441. [Google Scholar] [CrossRef] [Green Version]
  91. Hemming, S.; Cakouros, D.; Isenmann, S.; Cooper, L.; Menicanin, D.; Zannettino, A.; Gronthos, S. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification. Stem Cells 2014, 32, 802–815. [Google Scholar] [CrossRef]
  92. Hemming, S.; Cakouros, D.; Codrington, J.; Vandyke, K.; Arthur, A.; Zannettino, A.; Gronthos, S. EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture and structural integrity and accelerates remodeling. FASEB J. 2017, 31, 1011–1027. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Li, C.; Chai, Y.; Wang, L.; Gao, B.; Chen, H.; Gao, P.; Zhou, F.Q.; Luo, X.; Crane, J.L.; Yu, B.; et al. Programmed cell senescence in skeleton during late puberty. Nat. Commun. 2017, 8, 1312. [Google Scholar] [CrossRef] [Green Version]
  94. Hemming, S.; Cakouros, D.; Vandyke, K.; Davis, M.J.; Zannettino, A.C.; Gronthos, S. Identification of Novel EZH2 Targets Regulating Osteogenic Differentiation in Mesenchymal Stem Cells. Stem Cells Dev. 2016, 25, 909–921. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Su, X.; Zhang, H.; Lei, F.; Wang, R.; Lin, T.; Liao, L. Epigenetic therapy attenuates oxidative stress in BMSCs during ageing. J. Cell Mol. Med. 2022, 26, 375–384. [Google Scholar] [CrossRef] [PubMed]
  96. Fernandez, A.F.; Bayon, G.F.; Urdinguio, R.G.; Torano, E.G.; Garcia, M.G.; Carella, A.; Petrus-Reurer, S.; Ferrero, C.; Martinez-Camblor, P.; Cubillo, I.; et al. H3K4me1 marks DNA regions hypomethylated during aging in human stem and differentiated cells. Genome Res. 2015, 25, 27–40. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  97. Zhang, F.; Xu, L.; Xu, L.; Xu, Q.; Karsenty, G.; Chen, C.D. Histone demethylase JMJD3 is required for osteoblast differentiation in mice. Sci. Rep. 2015, 5, 13418. [Google Scholar] [CrossRef] [Green Version]
  98. Huang, B.; Wang, B.; Yuk-Wai Lee, W.; Pong, U.K.; Leung, K.T.; Li, X.; Liu, Z.; Chen, R.; Lin, J.C.; Tsang, L.L.; et al. KDM3A and KDM4C Regulate Mesenchymal Stromal Cell Senescence and Bone Aging via Condensin-mediated Heterochromatin Reorganization. iScience 2019, 21, 375–390. [Google Scholar] [CrossRef]
  99. Wang, C.; Wang, J.; Li, J.; Hu, G.; Shan, S.; Li, Q.; Zhang, X. KDM5A controls bone morphogenic protein 2-induced osteogenic differentiation of bone mesenchymal stem cells during osteoporosis. Cell Death Dis. 2016, 7, e2335. [Google Scholar] [CrossRef]
  100. Yin, B.; Yu, F.; Wang, C.; Li, B.; Liu, M.; Ye, L. Epigenetic Control of Mesenchymal Stem Cell Fate Decision via Histone Methyltransferase Ash1l. Stem Cells 2019, 37, 115–127. [Google Scholar] [CrossRef] [Green Version]
  101. Sun, X.J.; Wei, J.; Wu, X.Y.; Hu, M.; Wang, L.; Wang, H.H.; Zhang, Q.H.; Chen, S.J.; Huang, Q.H.; Chen, Z. Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. J. Biol. Chem. 2005, 280, 35261–35271. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  102. Wang, L.; Niu, N.; Li, L.; Shao, R.; Ouyang, H.; Zou, W. H3K36 trimethylation mediated by SETD2 regulates the fate of bone marrow mesenchymal stem cells. PLoS Biol. 2018, 16, e2006522. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  103. Liang, Y.; Liu, X.; Zhou, R.; Song, D.; Jiang, Y.Z.; Xue, W. Chaetocin Promotes Osteogenic Differentiation via Modulating Wnt/Beta-Catenin Signaling in Mesenchymal Stem Cells. Stem Cells Int. 2021, 2021, 8888416. [Google Scholar] [CrossRef] [PubMed]
  104. Zuo, B.; Zhu, J.; Li, J.; Wang, C.; Zhao, X.; Cai, G.; Li, Z.; Peng, J.; Wang, P.; Shen, C.; et al. microRNA-103a functions as a mechanosensitive microRNA to inhibit bone formation through targeting Runx2. J. Bone Miner Res. 2015, 30, 330–345. [Google Scholar] [CrossRef] [PubMed]
  105. Jung, J.W.; Lee, S.; Seo, M.S.; Park, S.B.; Kurtz, A.; Kang, S.K.; Kang, K.S. Histone deacetylase controls adult stem cell aging by balancing the expression of polycomb genes and jumonji domain containing 3. Cell Mol. Life Sci. 2010, 67, 1165–1176. [Google Scholar] [CrossRef] [Green Version]
  106. Zhang, M.; Yang, S.; Nelakanti, R.; Zhao, W.; Liu, G.; Li, Z.; Liu, X.; Wu, T.; Xiao, A.; Li, H. Mammalian ALKBH1 serves as an N6-mA demethylase of unpairing DNA. Cell Res. 2020, 30, 197–210. [Google Scholar] [CrossRef]
  107. Zhang, P.; Liu, Y.; Jin, C.; Zhang, M.; Lv, L.; Zhang, X.; Liu, H.; Zhou, Y. Histone H3K9 Acetyltransferase PCAF Is Essential for Osteogenic Differentiation Through Bone Morphogenetic Protein Signaling and May Be Involved in Osteoporosis. Stem Cells 2016, 34, 2332–2341. [Google Scholar] [CrossRef]
  108. Zhang, P.; Liu, Y.; Jin, C.; Zhang, M.; Tang, F.; Zhou, Y. Histone Acetyltransferase GCN5 Regulates Osteogenic Differentiation of Mesenchymal Stem Cells by Inhibiting NF-kappaB. J. Bone Miner Res. 2016, 31, 391–402. [Google Scholar] [CrossRef] [Green Version]
  109. Li, Z.; Liu, C.; Xie, Z.; Song, P.; Zhao, R.C.; Guo, L.; Liu, Z.; Wu, Y. Epigenetic dysregulation in mesenchymal stem cell aging and spontaneous differentiation. PLoS ONE 2011, 6, e20526. [Google Scholar] [CrossRef] [Green Version]
  110. Liu, G.; Chen, H.; Liu, H.; Zhang, W.; Zhou, J. Emerging roles of SIRT6 in human diseases and its modulators. Med. Res. Rev. 2021, 41, 1089–1137. [Google Scholar] [CrossRef]
  111. Pan, H.; Guan, D.; Liu, X.; Li, J.; Wang, L.; Wu, J.; Zhou, J.; Zhang, W.; Ren, R.; Zhang, W.; et al. SIRT6 safeguards human mesenchymal stem cells from oxidative stress by coactivating NRF2. Cell Res. 2016, 26, 190–205. [Google Scholar] [CrossRef]
  112. Baker, D.J.; Childs, B.G.; Durik, M.; Wijers, M.E.; Sieben, C.J.; Zhong, J.; Saltness, R.A.; Jeganathan, K.B.; Verzosa, G.C.; Pezeshki, A.; et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 2016, 530, 184–189. [Google Scholar] [CrossRef] [Green Version]
  113. Wang, W.; Zheng, Y.; Sun, S.; Li, W.; Song, M.; Ji, Q.; Wu, Z.; Liu, Z.; Fan, Y.; Liu, F.; et al. A genome-wide CRISPR-based screen identifies KAT7 as a driver of cellular senescence. Sci. Transl. Med. 2021, 13, eabd2655. [Google Scholar] [CrossRef] [PubMed]
  114. Sen, P.; Lan, Y.; Li, C.Y.; Sidoli, S.; Donahue, G.; Dou, Z.; Frederick, B.; Chen, Q.; Luense, L.J.; Garcia, B.A.; et al. Histone Acetyltransferase p300 Induces De Novo Super-Enhancers to Drive Cellular Senescence. Mol. Cell 2019, 73, 684–698.e688. [Google Scholar] [CrossRef] [Green Version]
  115. Kanfi, Y.; Naiman, S.; Amir, G.; Peshti, V.; Zinman, G.; Nahum, L.; Bar-Joseph, Z.; Cohen, H.Y. The sirtuin SIRT6 regulates lifespan in male mice. Nature 2012, 483, 218–221. [Google Scholar] [CrossRef]
  116. Xie, L.; Pelz, C.; Wang, W.; Bashar, A.; Varlamova, O.; Shadle, S.; Impey, S. KDM5B regulates embryonic stem cell self-renewal and represses cryptic intragenic transcription. EMBO J. 2011, 30, 1473–1484. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  117. Neri, F.; Rapelli, S.; Krepelova, A.; Incarnato, D.; Parlato, C.; Basile, G.; Maldotti, M.; Anselmi, F.; Oliviero, S. Intragenic DNA methylation prevents spurious transcription initiation. Nature 2017, 543, 72–77. [Google Scholar] [CrossRef] [PubMed]
  118. McCauley, B.S.; Sun, L.; Yu, R.; Lee, M.; Liu, H.; Leeman, D.S.; Huang, Y.; Webb, A.E.; Dang, W. Altered Chromatin States Drive Cryptic Transcription in Aging Mammalian Stem Cells. Nat. Aging 2021, 1, 684–697. [Google Scholar] [CrossRef]
  119. Kuehbacher, A.; Urbich, C.; Zeiher, A.M.; Dimmeler, S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ. Res. 2007, 101, 59–68. [Google Scholar] [CrossRef] [Green Version]
  120. Narayanan, A.; Srinaath, N.; Rohini, M.; Selvamurugan, N. Regulation of Runx2 by MicroRNAs in osteoblast differentiation. Life Sci. 2019, 232, 116676. [Google Scholar] [CrossRef]
  121. Li, C.L.; Wang, K.; Li, Z.W.; Xiong, Y.B.; Liu, J.H.; Meng, G.H.; Qin, F. MiR-105 enhances osteogenic differentiation of hADSCs via the targeted regulation of SOX9. Tissue Cell 2021, 72, 101540. [Google Scholar] [CrossRef] [PubMed]
  122. Portius, D.; Sobolewski, C.; Foti, M. MicroRNAs-Dependent Regulation of PPARs in Metabolic Diseases and Cancers. PPAR Res. 2017, 2017, 7058424. [Google Scholar] [CrossRef] [Green Version]
  123. Camp, E.; Pribadi, C.; Anderson, P.J.; Zannettino, A.C.W.; Gronthos, S. miRNA-376c-3p Mediates TWIST-1 Inhibition of Bone Marrow-Derived Stromal Cell Osteogenesis and Can Reduce Aberrant Bone Formation of TWIST-1 Haploinsufficient Calvarial Cells. Stem Cells Dev. 2018, 27, 1621–1633. [Google Scholar] [CrossRef] [PubMed]
  124. Li, W.; Chen, Z.; Cai, C.; Li, G.; Wang, X.; Shi, Z. MicroRNA-505 is involved in the regulation of osteogenic differentiation of MC3T3-E1 cells partially by targeting RUNX2. J. Orthop. Surg. Res. 2020, 15, 143. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  125. Zhang, Y.; Xie, R.L.; Croce, C.M.; Stein, J.L.; Lian, J.B.; van Wijnen, A.J.; Stein, G.S. A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. Proc. Natl. Acad. Sci. USA 2011, 108, 9863–9868. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  126. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843–854. [Google Scholar] [CrossRef]
  127. Guo, W.T.; Wang, Y. Dgcr8 knockout approaches to understand microRNA functions in vitro and in vivo. Cell Mol. Life Sci. 2019, 76, 1697–1711. [Google Scholar] [CrossRef]
  128. Jung, Y.-d.; Park, S.-K.; Kang, D.; Hwang, S.; Kang, M.-H.; Hong, S.-W.; Moon, J.-H.; Shin, J.-S.; Jin, D.-H.; You, D.; et al. Epigenetic regulation of miR-29a/miR-30c/DNMT3A axis controls SOD2 and mitochondrial oxidative stress in human mesenchymal stem cells. Redox Biol. 2020, 37, 101716. [Google Scholar] [CrossRef]
  129. Isenmann, S.; Arthur, A.; Zannettino, A.C.; Turner, J.L.; Shi, S.; Glackin, C.A.; Gronthos, S. TWIST family of basic helix-loop-helix transcription factors mediate human mesenchymal stem cell growth and commitment. Stem Cells 2009, 27, 2457–2468. [Google Scholar] [CrossRef]
  130. Guo, Y.; Li, L.; Gao, J.; Chen, X.; Sang, Q. miR-214 suppresses the osteogenic differentiation of bone marrow-derived mesenchymal stem cells and these effects are mediated through the inhibition of the JNK and p38 pathways. Int. J. Mol. Med. 2017, 39, 71–80. [Google Scholar] [CrossRef] [Green Version]
  131. Liu, J.; Li, Y.; Luo, M.; Yuan, Z.; Liu, J. MicroRNA-214 inhibits the osteogenic differentiation of human osteoblasts through the direct regulation of baculoviral IAP repeat-containing 7. Exp. Cell Res. 2017, 351, 157–162. [Google Scholar] [CrossRef] [PubMed]
  132. Chen, R.; Qiu, H.; Tong, Y.; Liao, F.; Hu, X.; Qiu, Y.; Liao, Y. MiRNA-19a-3p alleviates the progression of osteoporosis by targeting HDAC4 to promote the osteogenic differentiation of hMSCs. Biochem. Biophys. Res. Commun. 2019, 516, 666–672. [Google Scholar] [CrossRef] [PubMed]
  133. Li, X.; Xie, W.; Xie, C.; Huang, C.; Zhu, J.; Liang, Z.; Deng, F.; Zhu, M.; Zhu, W.; Wu, R. Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation. Phytother. Res. 2014, 28, 1553–1560. [Google Scholar] [CrossRef] [PubMed]
  134. Li, R.; Liang, L.; Dou, Y.; Huang, Z.; Mo, H.; Wang, Y.; Yu, B. Mechanical stretch inhibits mesenchymal stem cell adipogenic differentiation through TGFbeta1/Smad2 signaling. J. Biomech. 2015, 48, 3665–3671. [Google Scholar] [CrossRef]
  135. Wang, F.; Li, T.; Zhang, B.; Li, H.; Wu, Q.; Yang, L.; Nie, Y.; Wu, K.; Shi, Y.; Fan, D. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem. Biophys. Res. Commun. 2013, 434, 688–694. [Google Scholar] [CrossRef] [PubMed]
  136. Wu, Y.; Hou, F.; Wang, X.; Kong, Q.; Han, X.; Bai, B. Aberrant Expression of Histone Deacetylases 4 in Cognitive Disorders: Molecular Mechanisms and a Potential Target. Front. Mol. Neurosci. 2016, 9, 114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  137. Zheng, H.; Liu, J.; Tycksen, E.; Nunley, R.; McAlinden, A. MicroRNA-181a/b-1 over-expression enhances osteogenesis by modulating PTEN/PI3K/AKT signaling and mitochondrial metabolism. Bone 2019, 123, 92–102. [Google Scholar] [CrossRef]
  138. McGonnell, I.M.; Grigoriadis, A.E.; Lam, E.W.-F.; Price, J.S.; Sunters, A. A specific role for phosphoinositide 3-kinase and AKT in osteoblasts? Front. Endocrinol. 2012, 3, 88. [Google Scholar] [CrossRef] [Green Version]
  139. Ghosh-Choudhury, N.; Abboud, S.L.; Nishimura, R.; Celeste, A.; Mahimainathan, L.; Choudhury, G.G. Requirement of BMP-2-induced phosphatidylinositol 3-kinase and Akt serine/threonine kinase in osteoblast differentiation and Smad-dependent BMP-2 gene transcription. J. Biol. Chem. 2002, 277, 33361–33368. [Google Scholar] [CrossRef] [Green Version]
  140. Wang, C.; Liao, H.; Cao, Z. Role of Osterix and MicroRNAs in Bone Formation and Tooth Development. Med. Sci. Monit. 2016, 22, 2934–2942. [Google Scholar] [CrossRef] [Green Version]
  141. Eskildsen, T.; Taipaleenmaki, H.; Stenvang, J.; Abdallah, B.M.; Ditzel, N.; Nossent, A.Y.; Bak, M.; Kauppinen, S.; Kassem, M. MicroRNA-138 regulates osteogenic differentiation of human stromal (mesenchymal) stem cells in vivo. Proc. Natl. Acad. Sci. USA 2011, 108, 6139–6144. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  142. Arthur, A.; Gronthos, S. Clinical Application of Bone Marrow Mesenchymal Stem/Stromal Cells to Repair Skeletal Tissue. Int. J. Mol. Sci. 2020, 21, 9759. [Google Scholar] [CrossRef]
  143. Yang, L.; Lin, C.; Liu, W.; Zhang, J.; Ohgi, K.A.; Grinstein, J.D.; Dorrestein, P.C.; Rosenfeld, M.G. ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell 2011, 147, 773–788. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  144. Statello, L.; Guo, C.-J.; Chen, L.-L.; Huarte, M. Gene regulation by long non-coding RNAs and its biological functions. Nat. Rev. Mol. Cell Biol. 2021, 22, 96–118. [Google Scholar] [CrossRef] [PubMed]
  145. Roglic, G. WHO Global report on diabetes: A summary. Int. J. Noncommunicable Dis. 2016, 1, 3. [Google Scholar] [CrossRef]
  146. Bruder, S.P.; Jaiswal, N.; Haynesworth, S.E. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J. Cell Biochem. 1997, 64, 278–294. [Google Scholar] [CrossRef]
  147. Jackuliak, P.; Payer, J. Osteoporosis, fractures, and diabetes. Int. J. Endocrinol. 2014, 2014, 820615. [Google Scholar] [CrossRef] [Green Version]
  148. Sirois, I.; Cheung, A.M.; Ward, W.E. Biomechanical bone strength and bone mass in young male and female rats fed a fish oil diet. Prostaglandins Leukot Essent Fat. Acids 2003, 68, 415–421. [Google Scholar] [CrossRef]
  149. Zernicke, R.F.; Salem, G.J.; Barnard, R.J.; Schramm, E. Long-term, high-fat-sucrose diet alters rat femoral neck and vertebral morphology, bone mineral content, and mechanical properties. Bone 1995, 16, 25–31. [Google Scholar] [CrossRef]
  150. Lac, G.; Cavalie, H.; Ebal, E.; Michaux, O. Effects of a high fat diet on bone of growing rats. Correlations between visceral fat, adiponectin and bone mass density. Lipids Health Dis. 2008, 7, 16. [Google Scholar] [CrossRef] [Green Version]
  151. Koo, W.W.; Hammami, M.; Margeson, D.P.; Nwaesei, C.; Montalto, M.B.; Lasekan, J.B. Reduced bone mineralization in infants fed palm olein-containing formula: A randomized, double-blinded, prospective trial. Pediatrics 2003, 111, 1017–1023. [Google Scholar] [CrossRef]
  152. Barker, D.J. The origins of the developmental origins theory. J. Intern. Med. 2007, 261, 412–417. [Google Scholar] [CrossRef]
  153. McCurdy, C.E.; Bishop, J.M.; Williams, S.M.; Grayson, B.E.; Smith, M.S.; Friedman, J.E.; Grove, K.L. Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates. J. Clin. Investig. 2009, 119, 323–335. [Google Scholar] [CrossRef] [Green Version]
  154. Samuelsson, A.M.; Matthews, P.A.; Argenton, M.; Christie, M.R.; McConnell, J.M.; Jansen, E.H.; Piersma, A.H.; Ozanne, S.E.; Twinn, D.F.; Remacle, C.; et al. Diet-induced obesity in female mice leads to offspring hyperphagia, adiposity, hypertension, and insulin resistance: A novel murine model of developmental programming. Hypertension 2008, 51, 383–392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  155. Chen, D.; Shen, J.; Zhao, W.; Wang, T.; Han, L.; Hamilton, J.L.; Im, H.J. Osteoarthritis: Toward a comprehensive understanding of pathological mechanism. Bone Res. 2017, 5, 16044. [Google Scholar] [CrossRef]
  156. Shankar, K.; Harrell, A.; Liu, X.; Gilchrist, J.M.; Ronis, M.J.; Badger, T.M. Maternal obesity at conception programs obesity in the offspring. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 294, R528–R538. [Google Scholar] [CrossRef]
  157. Geraghty, A.A.; Lindsay, K.L.; Alberdi, G.; McAuliffe, F.M.; Gibney, E.R. Nutrition During Pregnancy Impacts Offspring’s Epigenetic Status-Evidence from Human and Animal Studies. Nutr. Metab. Insights 2015, 8, 41–47. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  158. Montecino, M.; Stein, G.; Stein, J.; Zaidi, K.; Aguilar, R. Multiple levels of epigenetic control for bone biology and pathology. Bone 2015, 81, 733–738. [Google Scholar] [CrossRef] [Green Version]
  159. Bose, D.A.; Donahue, G.; Reinberg, D.; Shiekhattar, R.; Bonasio, R.; Berger, S.L. RNA Binding to CBP Stimulates Histone Acetylation and Transcription. Cell 2017, 168, 135–149.e122. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  160. Chen, J.R.; Caviness, P.C.; Zhao, H.; Belcher, B.; Wankhade, U.D.; Shankar, K.; Blackburn, M.L.; Lazarenko, O.P. Maternal high-fat diet modifies epigenetic marks H3K27me3 and H3K27ac in bone to regulate offspring osteoblastogenesis in mice. Epigenetics 2022, 17, 2209–2222. [Google Scholar] [CrossRef] [PubMed]
  161. Etchegaray, J.P.; Mostoslavsky, R. Interplay between Metabolism and Epigenetics: A Nuclear Adaptation to Environmental Changes. Mol. Cell 2016, 62, 695–711. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  162. Clemens, T.L.; Karsenty, G. The osteoblast: An insulin target cell controlling glucose homeostasis. J. Bone Miner Res. 2011, 26, 677–680. [Google Scholar] [CrossRef]
  163. Lee, N.K.; Sowa, H.; Hinoi, E.; Ferron, M.; Ahn, J.D.; Confavreux, C.; Dacquin, R.; Mee, P.J.; McKee, M.D.; Jung, D.Y.; et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130, 456–469. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  164. Ferron, M.; Hinoi, E.; Karsenty, G.; Ducy, P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl. Acad. Sci. USA 2008, 105, 5266–5270. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  165. Florencio-Silva, R.; Sasso, G.R.; Sasso-Cerri, E.; Simoes, M.J.; Cerri, P.S. Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. Biomed. Res. Int. 2015, 2015, 421746. [Google Scholar] [CrossRef] [Green Version]
  166. Park-Min, K.H. Epigenetic regulation of bone cells. Connect Tissue Res. 2017, 58, 76–89. [Google Scholar] [CrossRef] [Green Version]
  167. Faienza, M.F.; Luce, V.; Ventura, A.; Colaianni, G.; Colucci, S.; Cavallo, L.; Grano, M.; Brunetti, G. Skeleton and glucose metabolism: A bone-pancreas loop. Int. J. Endocrinol. 2015, 2015, 758148. [Google Scholar] [CrossRef] [Green Version]
  168. Gerdhem, P.; Isaksson, A.; Akesson, K.; Obrant, K.J. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos. Int. 2005, 16, 1506–1512. [Google Scholar] [CrossRef] [Green Version]
  169. Kindblom, J.M.; Ohlsson, C.; Ljunggren, O.; Karlsson, M.K.; Tivesten, A.; Smith, U.; Mellstrom, D. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J. Bone Miner Res. 2009, 24, 785–791. [Google Scholar] [CrossRef]
  170. Kanazawa, I.; Yamaguchi, T.; Yamamoto, M.; Yamauchi, M.; Kurioka, S.; Yano, S.; Sugimoto, T. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2009, 94, 45–49. [Google Scholar] [CrossRef] [Green Version]
  171. Genetos, D.C.; Zhou, Z.; Li, Z.; Donahue, H.J. Age-related changes in gap junctional intercellular communication in osteoblastic cells. J. Orthop. Res. 2012, 30, 1979–1984. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  172. Ginty, F. Dietary protein and bone health. Proc. Nutr. Soc. 2003, 62, 867–876. [Google Scholar] [CrossRef] [PubMed]
  173. Kerstetter, J.E.; O’Brien, K.; Insogna, K. Dietary protein and intestinal calcium absorption. Am. J. Clin. Nutr. 2001, 73, 990–992. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  174. Bonjour, J.P.; Ammann, P.; Chevalley, T.; Rizzoli, R. Protein intake and bone growth. Can. J. Appl. Physiol. 2001, 26, S153–S166. [Google Scholar] [CrossRef] [PubMed]
  175. Mi, H.; Li, H.; Jiang, W.; Song, W.; Yan, Q.; He, Z.; Tan, Z. Calcium Homeostasis and Bone Metabolism in Goats Fed a Low Protein Diet. Front. Vet Sci. 2021, 8, 829872. [Google Scholar] [CrossRef]
  176. Lanham, S.A.; Smith, S.J.; Watkins, A.J.; Lucas, E.S.; MacCaoilte, N.; Oreffo, R.O.C.; Fleming, T.P.; Eckert, J.J. Periconception maternal low-protein diet adversely affects male mouse fetal bone growth and mineral density quality in late gestation. J. Dev. Orig. Health Dis. 2021, 12, 384–395. [Google Scholar] [CrossRef]
  177. Watkins, A.J.; Sirovica, S.; Stokes, B.; Isaacs, M.; Addison, O.; Martin, R.A. Paternal low protein diet programs preimplantation embryo gene expression, fetal growth and skeletal development in mice. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 1371–1381. [Google Scholar] [CrossRef]
  178. Chen, J.; Astle, C.M.; Harrison, D.E. Hematopoietic senescence is postponed and hematopoietic stem cell function is enhanced by dietary restriction. Exp. Hematol. 2003, 31, 1097–1103. [Google Scholar] [CrossRef]
  179. Kane, A.E.; Sinclair, D.A. Epigenetic changes during aging and their reprogramming potential. Crit. Rev. Biochem. Mol. Biol. 2019, 54, 61–83. [Google Scholar] [CrossRef]
  180. Stubbs, T.M.; Bonder, M.J.; Stark, A.K.; Krueger, F.; Team, B.I.A.C.; von Meyenn, F.; Stegle, O.; Reik, W. Multi-tissue DNA methylation age predictor in mouse. Genome Biol. 2017, 18, 68. [Google Scholar] [CrossRef] [Green Version]
  181. Fontana, L.; Partridge, L.; Longo, V.D. Extending healthy life span--from yeast to humans. Science 2010, 328, 321–326. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  182. Harrison, D.E.; Strong, R.; Sharp, Z.D.; Nelson, J.F.; Astle, C.M.; Flurkey, K.; Nadon, N.L.; Wilkinson, J.E.; Frenkel, K.; Carter, C.S.; et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460, 392–395. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  183. Berger, S.L.; Sassone-Corsi, P. Metabolic Signaling to Chromatin. Cold Spring Harb. Perspect. Biol. 2016, 8, a019463. [Google Scholar] [CrossRef]
  184. Tatar, M.; Sedivy, J.M. Mitochondria: Masters of Epigenetics. Cell 2016, 165, 1052–1054. [Google Scholar] [CrossRef] [Green Version]
  185. Verdin, E. NAD(+) in aging, metabolism, and neurodegeneration. Science 2015, 350, 1208–1213. [Google Scholar] [CrossRef]
  186. Imai, S.; Guarente, L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014, 24, 464–471. [Google Scholar] [CrossRef]
  187. Sart, S.; Song, L.; Li, Y. Controlling Redox Status for Stem Cell Survival, Expansion, and Differentiation. Oxid. Med. Cell Longev. 2015, 2015, 105135. [Google Scholar] [CrossRef] [Green Version]
  188. Chen, C.T.; Shih, Y.R.; Kuo, T.K.; Lee, O.K.; Wei, Y.H. Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells. Stem Cells 2008, 26, 960–968. [Google Scholar] [CrossRef]
  189. Pattappa, G.; Thorpe, S.D.; Jegard, N.C.; Heywood, H.K.; de Bruijn, J.D.; Lee, D.A. Continuous and uninterrupted oxygen tension influences the colony formation and oxidative metabolism of human mesenchymal stem cells. Tissue Eng. Part C Methods 2013, 19, 68–79. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  190. Klotz, L.O.; Sanchez-Ramos, C.; Prieto-Arroyo, I.; Urbanek, P.; Steinbrenner, H.; Monsalve, M. Redox regulation of FoxO transcription factors. Redox Biol. 2015, 6, 51–72. [Google Scholar] [CrossRef] [Green Version]
  191. Leucht, P.; Kim, J.B.; Amasha, R.; James, A.W.; Girod, S.; Helms, J.A. Embryonic origin and Hox status determine progenitor cell fate during adult bone regeneration. Development 2008, 135, 2845–2854. [Google Scholar] [CrossRef] [Green Version]
  192. Rubin, C.; Turner, A.S.; Bain, S.; Mallinckrodt, C.; McLeod, K. Anabolism. Low mechanical signals strengthen long bones. Nature 2001, 412, 603–604. [Google Scholar] [CrossRef]
  193. Rubin, C.T.; Capilla, E.; Luu, Y.K.; Busa, B.; Crawford, H.; Nolan, D.J.; Mittal, V.; Rosen, C.J.; Pessin, J.E.; Judex, S. Adipogenesis is inhibited by brief, daily exposure to high-frequency, extremely low-magnitude mechanical signals. Proc. Natl. Acad. Sci. USA 2007, 104, 17879–17884. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  194. Rubin, J.; Murphy, T.; Nanes, M.S.; Fan, X. Mechanical strain inhibits expression of osteoclast differentiation factor by murine stromal cells. Am. J. Physiol. Cell Physiol. 2000, 278, C1126–C1132. [Google Scholar] [CrossRef] [PubMed]
  195. Judex, S.; Gross, T.S.; Zernicke, R.F. Strain gradients correlate with sites of exercise-induced bone-forming surfaces in the adult skeleton. J. Bone Miner Res. 1997, 12, 1737–1745. [Google Scholar] [CrossRef] [PubMed]
  196. Baglio, S.R.; Rooijers, K.; Koppers-Lalic, D.; Verweij, F.J.; Pérez Lanzón, M.; Zini, N.; Naaijkens, B.; Perut, F.; Niessen, H.W.M.; Baldini, N.; et al. Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Res. Ther. 2015, 6, 127. [Google Scholar] [CrossRef] [Green Version]
  197. Styner, M.; Meyer, M.B.; Galior, K.; Case, N.; Xie, Z.; Sen, B.; Thompson, W.R.; Pike, J.W.; Rubin, J. Mechanical strain downregulates C/EBPbeta in MSC and decreases endoplasmic reticulum stress. PLoS ONE 2012, 7, e51613. [Google Scholar] [CrossRef]
  198. Styner, M.; Pagnotti, G.M.; Galior, K.; Wu, X.; Thompson, W.R.; Uzer, G.; Sen, B.; Xie, Z.; Horowitz, M.C.; Styner, M.A.; et al. Exercise Regulation of Marrow Fat in the Setting of PPARgamma Agonist Treatment in Female C57BL/6 Mice. Endocrinology 2015, 156, 2753–2761. [Google Scholar] [CrossRef] [Green Version]
  199. McGrath, C.; Sankaran, J.S.; Misaghian-Xanthos, N.; Sen, B.; Xie, Z.; Styner, M.A.; Zong, X.; Rubin, J.; Styner, M. Exercise Degrades Bone in Caloric Restriction, Despite Suppression of Marrow Adipose Tissue (MAT). J. Bone Miner Res. 2020, 35, 106–115. [Google Scholar] [CrossRef]
  200. Bertheau, R.C.; Lorbeer, R.; Nattenmuller, J.; Wintermeyer, E.; Machann, J.; Linkohr, B.; Peters, A.; Bamberg, F.; Schlett, C.L. Bone marrow fat fraction assessment in regard to physical activity: KORA FF4-3-T MR imaging in a population-based cohort. Eur. Radiol. 2020, 30, 3417–3428. [Google Scholar] [CrossRef]
  201. Belavy, D.L.; Quittner, M.J.; Ridgers, N.D.; Shiekh, A.; Rantalainen, T.; Trudel, G. Specific Modulation of Vertebral Marrow Adipose Tissue by Physical Activity. J. Bone Miner Res. 2018, 33, 651–657. [Google Scholar] [CrossRef] [PubMed]
  202. Fonseca, H.; Moreira-Goncalves, D.; Esteves, J.L.; Viriato, N.; Vaz, M.; Mota, M.P.; Duarte, J.A. Voluntary exercise has long-term in vivo protective effects on osteocyte viability and bone strength following ovariectomy. Calcif. Tissue Int. 2011, 88, 443–454. [Google Scholar] [CrossRef] [PubMed]
  203. Rubin, J.; Styner, M.; Uzer, G. Physical Signals May Affect Mesenchymal Stem Cell Differentiation via Epigenetic Controls. Exerc. Sport Sci. Rev. 2018, 46, 42–47. [Google Scholar] [CrossRef] [PubMed]
  204. Chen, X.; Zhu, X.; Wei, A.; Chen, F.; Gao, Q.; Lu, K.; Jiang, Q.; Cao, W. Nrf2 epigenetic derepression induced by running exercise protects against osteoporosis. Bone Res. 2021, 9, 15. [Google Scholar] [CrossRef]
  205. Arnsdorf, E.J.; Tummala, P.; Castillo, A.B.; Zhang, F.; Jacobs, C.R. The epigenetic mechanism of mechanically induced osteogenic differentiation. J. Biomech. 2010, 43, 2881–2886. [Google Scholar] [CrossRef] [Green Version]
  206. Lindholm, M.E.; Marabita, F.; Gomez-Cabrero, D.; Rundqvist, H.; Ekstrom, T.J.; Tegner, J.; Sundberg, C.J. An integrative analysis reveals coordinated reprogramming of the epigenome and the transcriptome in human skeletal muscle after training. Epigenetics 2014, 9, 1557–1569. [Google Scholar] [CrossRef]
  207. Ronn, T.; Volkov, P.; Davegardh, C.; Dayeh, T.; Hall, E.; Olsson, A.H.; Nilsson, E.; Tornberg, A.; Dekker Nitert, M.; Eriksson, K.F.; et al. A six months exercise intervention influences the genome-wide DNA methylation pattern in human adipose tissue. PLoS Genet. 2013, 9, e1003572. [Google Scholar] [CrossRef]
  208. Ntanasis-Stathopoulos, J.; Tzanninis, J.G.; Philippou, A.; Koutsilieris, M. Epigenetic regulation on gene expression induced by physical exercise. J. Musculoskelet Neuronal Interact 2013, 13, 133–146. [Google Scholar]
  209. Nakajima, K.; Takeoka, M.; Mori, M.; Hashimoto, S.; Sakurai, A.; Nose, H.; Higuchi, K.; Itano, N.; Shiohara, M.; Oh, T.; et al. Exercise effects on methylation of ASC gene. Int. J. Sports Med. 2010, 31, 671–675. [Google Scholar] [CrossRef] [Green Version]
Ijms 24 06499 g001 550
Figure 1. Molecular regulation of MSC cell fate. MSC differentiation is driven by a number of master regulators into the various lineages, including osteoblasts (Runx2), adipocytes (PPARy2) and chondroblasts (Sox9). Aged MSC show changes in phenotypes and differentiation properties, an effect of the changing epigenetic landscape within the cell.
Figure 1. Molecular regulation of MSC cell fate. MSC differentiation is driven by a number of master regulators into the various lineages, including osteoblasts (Runx2), adipocytes (PPARy2) and chondroblasts (Sox9). Aged MSC show changes in phenotypes and differentiation properties, an effect of the changing epigenetic landscape within the cell.
Ijms 24 06499 g001
Ijms 24 06499 g002 550
Figure 2. Regulators of DNA methylation. CpG methylation and the factors involved in writing (DNMT), reading (MBD containing proteins) and executing the silencing of genes (repressors). This mark is able to be removed or inhibited by the activity of DNA hydroxymethylases (TETs) and miRNA targeting DNMT. Receptor Activator of Nuclear Factor-kappa B (RANK).
Figure 2. Regulators of DNA methylation. CpG methylation and the factors involved in writing (DNMT), reading (MBD containing proteins) and executing the silencing of genes (repressors). This mark is able to be removed or inhibited by the activity of DNA hydroxymethylases (TETs) and miRNA targeting DNMT. Receptor Activator of Nuclear Factor-kappa B (RANK).
Ijms 24 06499 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Smith, N.; Shirazi, S.; Cakouros, D.; Gronthos, S. Impact of Environmental and Epigenetic Changes on Mesenchymal Stem Cells during Aging. Int. J. Mol. Sci. 2023, 24, 6499. https://doi.org/10.3390/ijms24076499

AMA Style

Smith N, Shirazi S, Cakouros D, Gronthos S. Impact of Environmental and Epigenetic Changes on Mesenchymal Stem Cells during Aging. International Journal of Molecular Sciences. 2023; 24(7):6499. https://doi.org/10.3390/ijms24076499

Chicago/Turabian Style

Smith, Nicholas, Suzanna Shirazi, Dimitrios Cakouros, and Stan Gronthos. 2023. "Impact of Environmental and Epigenetic Changes on Mesenchymal Stem Cells during Aging" International Journal of Molecular Sciences 24, no. 7: 6499. https://doi.org/10.3390/ijms24076499

APA Style

Smith, N., Shirazi, S., Cakouros, D., & Gronthos, S. (2023). Impact of Environmental and Epigenetic Changes on Mesenchymal Stem Cells during Aging. International Journal of Molecular Sciences, 24(7), 6499. https://doi.org/10.3390/ijms24076499

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop